Search

Your search keyword '"Gallie, A."' showing total 304 results
Start Over Author "Gallie, A." Publisher elsevier bv
304 results on '"Gallie, A."'

2. Metastatic Death Based on Presenting Features and Treatment for Advanced Intraocular Retinoblastoma

Author

Ankit Singh Tomar, Paul T. Finger, Brenda Gallie, Tero T. Kivelä, Ashwin Mallipatna, Chengyue Zhang, Junyang Zhao, Matthew W. Wilson, Rachel C. Brennan, Michala Burges, Jonathan Kim, Jesse L. Berry, Rima Jubran, Vikas Khetan, Suganeswari Ganesan, Andrey Yarovoy, Vera Yarovaya, Elena Kotova, Denis Volodin, Yacoub A. Yousef, Kalle Nummi, Tatiana L. Ushakova, Olga V. Yugay, Vladimir G. Polyakov, Marco A. Ramirez-Ortiz, Elizabeth Esparza-Aguiar, Guillermo Chantada, Paula Schaiquevich, Adriana Fandino, Jason C. Yam, Winnie W. Lau, Carol P. Lam, Phillipa Sharwood, Sonia Moorthy, Quah Boon Long, Vera Adobea Essuman, Lorna A. Renner, Ekaterina Semenova, Jaume Català-Mora, Genoveva Correa-Llano, and Elisa Carreras

Subjects
Ophthalmology
Published
2022

3. High-risk Pathologic Features Based on Presenting Findings in Advanced Intraocular Retinoblastoma

Author

Ankit Singh Tomar, Paul T. Finger, Brenda Gallie, Tero T. Kivelä, Ashwin Mallipatna, Chengyue Zhang, Junyang Zhao, Matthew W. Wilson, Rachel C. Brennan, Michala Burges, Jonathan Kim, Jesse L. Berry, Rima Jubran, Vikas Khetan, Suganeswari Ganesan, Andrey Yarovoy, Vera Yarovaya, Elena Kotova, Denis Volodin, Yacoub A. Yousef, Kalle Nummi, Tatiana L. Ushakova, Olga V. Yugay, Vladimir G. Polyakov, Marco A. Ramirez-Ortiz, Elizabeth Esparza-Aguiar, Guillermo Chantada, Paula Schaiquevich, Adriana Fandino, Jason C. Yam, Winnie W. Lau, Carol P. Lam, Phillipa Sharwood, Sonia Moorthy, Quah Boon Long, Vera Adobea Essuman, Lorna A. Renner, Ekaterina Semenova, Jaume Català-Mora, Genoveva Correa-Llano, and Elisa Carreras

Subjects
Ophthalmology
Published
2022

4. Pediatric Cataract Surgery Following Treatment for Retinoblastoma: A Case Series and Systematic Review

Author

Stephanie N. Kletke, Ashwin Mallipatna, Kamiar Mireskandari, Brenda L. Gallie, and Asim Ali

Subjects
Male, Retinal Neoplasms, Retinoblastoma, Visual Acuity, Infant, Cataract Extraction, Capsule Opacification, Cataract, Ophthalmology, Postoperative Complications, Lens Implantation, Intraocular, Child, Preschool, Vitrectomy, Humans, Child, Retrospective Studies
Abstract

To determine the visual and refractive outcomes and the ocular and systemic complications of cataract surgery in eyes treated for retinoblastoma.Retrospective consecutive case series and systematic review.Children18 years of age with retinoblastoma who underwent surgery for secondary cataract between 2000 and 2020 were reviewed. Medline (OVID), Embase, Web of Science, and the Cochrane database were searched from inception to August 2020.A total of 15 eyes of 15 children were included. The mean age at retinoblastoma diagnosis was 12 months (median, 14; interquartile range [IQR], 4-19). Cataract developed at a mean age of 39 months (median, 31; IQR, 20-52), secondary to multiple treatments (n = 7), pars-plana vitrectomy (n = 3), external-beam radiotherapy (n = 2), laser (n = 2), and retinal detachment (n = 1). The mean preoperative quiescent interval was 44 months (median, 28; IQR, 15-64). Primary intraocular lens implantation was performed in 93%, posterior capsulotomy in 40%, and anterior vitrectomy in 33% of participants. Postoperatively, 100% had improved fundus visibility and 73% had improved vision. Complications included visual axis opacification (11 of 15), capsular phimosis (5 of 15), and zonulopathy (3 of 15). No patient developed intraocular recurrence, extraocular extension, or metastasis at a mean of 76 months (median, 78; IQR, 29-128) follow-up. The systematic review identified 852 studies, with 18 meeting inclusion criteria. Across all studies (n = 220 children), intraocular recurrence occurred in 6%, globe salvage in 91%, and extraocular extension and metastasis in1%.Modern retinoblastoma therapies, including intravitreal chemotherapy and vitrectomy, cause secondary cataract. Following cataract surgery, intraocular recurrence risk is low and extraocular spread is rare. Although surgery improves tumor visualization, visual prognosis may be limited by several factors. Challenges include biometry limitations and a high incidence of zonulopathy.

Published
2022

5. Reply

Author

Finger, Paul T., primary, Tomar, Ankit S., additional, Gallie, Brenda, additional, Kivelä, Tero T., additional, Mallipatna, Ashwin, additional, Zhang, Chengyue, additional, Zhao, Junyang, additional, Wilson, Matthew W., additional, Brennan, Rachel C., additional, Burges, Michala, additional, Kim, Jonathan, additional, Berry, Jesse L., additional, Jubran, Rima, additional, Khetan, Vikas, additional, Ganesan, Suganeswari, additional, Yarovoy, Andrey, additional, Yarovaya, Vera, additional, Kotova, Elena, additional, Volodin, Denis, additional, Yousef, Yacoub A., additional, Nummi, Kalle, additional, Ushakova, Tatiana L., additional, Yugay, Olga V., additional, Polyakov, Vladimir G., additional, Ramirez-Ortiz, Marco A., additional, Esparza-Aguiar, Elizabeth, additional, Chantada, Guillermo, additional, Schaiquevich, Paula, additional, Fandino, Adriana, additional, Yam, Jason C., additional, Lau, Winnie W., additional, Lam, Carol P., additional, Sharwood, Phillipa, additional, Moorthy, Sonia, additional, Long, Quah Boon, additional, Essuman, Vera Adobea, additional, Renner, Lorna A., additional, Semenova, Ekaterina, additional, Català-Mora, Jaume, additional, Correa-Llano, Genoveva, additional, and Carreras, Elisa, additional

Published
2023
Full Text
View/download PDF

7. Reply

Author

Paul T. Finger, Ankit S. Tomar, Brenda Gallie, Tero T. Kivelä, Ashwin Mallipatna, Chengyue Zhang, Junyang Zhao, Matthew W. Wilson, Rachel C. Brennan, Michala Burges, Jonathan Kim, Jesse L. Berry, Rima Jubran, Vikas Khetan, Suganeswari Ganesan, Andrey Yarovoy, Vera Yarovaya, Elena Kotova, Denis Volodin, Yacoub A. Yousef, Kalle Nummi, Tatiana L. Ushakova, Olga V. Yugay, Vladimir G. Polyakov, Marco A. Ramirez-Ortiz, Elizabeth Esparza-Aguiar, Guillermo Chantada, Paula Schaiquevich, Adriana Fandino, Jason C. Yam, Winnie W. Lau, Carol P. Lam, Phillipa Sharwood, Sonia Moorthy, Quah Boon Long, Vera Adobea Essuman, Lorna A. Renner, Ekaterina Semenova, Jaume Català-Mora, Genoveva Correa-Llano, and Elisa Carreras

Subjects
Ophthalmology
Published
2023

8. Metastatic Death Based on Presenting Features and Treatment for Advanced Intraocular Retinoblastoma

Author

Tomar, Ankit Singh, primary, Finger, Paul T., additional, Gallie, Brenda, additional, Kivelä, Tero T., additional, Mallipatna, Ashwin, additional, Zhang, Chengyue, additional, Zhao, Junyang, additional, Wilson, Matthew W., additional, Brennan, Rachel C., additional, Burges, Michala, additional, Kim, Jonathan, additional, Berry, Jesse L., additional, Jubran, Rima, additional, Khetan, Vikas, additional, Ganesan, Suganeswari, additional, Yarovoy, Andrey, additional, Yarovaya, Vera, additional, Kotova, Elena, additional, Volodin, Denis, additional, Yousef, Yacoub A., additional, Nummi, Kalle, additional, Ushakova, Tatiana L., additional, Yugay, Olga V., additional, Polyakov, Vladimir G., additional, Ramirez-Ortiz, Marco A., additional, Esparza-Aguiar, Elizabeth, additional, Chantada, Guillermo, additional, Schaiquevich, Paula, additional, Fandino, Adriana, additional, Yam, Jason C., additional, Lau, Winnie W., additional, Lam, Carol P., additional, Sharwood, Phillipa, additional, Moorthy, Sonia, additional, Long, Quah Boon, additional, Essuman, Vera Adobea, additional, Renner, Lorna A., additional, Semenova, Ekaterina, additional, Català-Mora, Jaume, additional, Correa-Llano, Genoveva, additional, and Carreras, Elisa, additional

Published
2022
Full Text
View/download PDF

10. High-risk Pathologic Features Based on Presenting Findings in Advanced Intraocular Retinoblastoma

Author

Tomar, Ankit Singh, primary, Finger, Paul T., additional, Gallie, Brenda, additional, Kivelä, Tero T., additional, Mallipatna, Ashwin, additional, Zhang, Chengyue, additional, Zhao, Junyang, additional, Wilson, Matthew W., additional, Brennan, Rachel C., additional, Burges, Michala, additional, Kim, Jonathan, additional, Berry, Jesse L., additional, Jubran, Rima, additional, Khetan, Vikas, additional, Ganesan, Suganeswari, additional, Yarovoy, Andrey, additional, Yarovaya, Vera, additional, Kotova, Elena, additional, Volodin, Denis, additional, Yousef, Yacoub A., additional, Nummi, Kalle, additional, Ushakova, Tatiana L., additional, Yugay, Olga V., additional, Polyakov, Vladimir G., additional, Ramirez-Ortiz, Marco A., additional, Esparza-Aguiar, Elizabeth, additional, Chantada, Guillermo, additional, Schaiquevich, Paula, additional, Fandino, Adriana, additional, Yam, Jason C., additional, Lau, Winnie W., additional, Lam, Carol P., additional, Sharwood, Phillipa, additional, Moorthy, Sonia, additional, Long, Quah Boon, additional, Essuman, Vera Adobea, additional, Renner, Lorna A., additional, Semenova, Ekaterina, additional, Català-Mora, Jaume, additional, Correa-Llano, Genoveva, additional, and Carreras, Elisa, additional

Published
2022
Full Text
View/download PDF

11. Global Retinoblastoma Treatment Outcomes

Author

Ekaterina Semenova, Kalle Nummi, Olga V Yugay, Carol P. S. Lam, Suganeswari Ganesan, Adriana Fandiño, Guillermo Chantada, Tero Kivelä, Elisa Carreras, Michala Burges, Phillipa Sharwood, V.G. Polyakov, Paula Schaiquevich, Vera Adobea Essuman, Quah Boon Long, Vera Yarovaya, Brenda L. Gallie, Rachel C. Brenna, Jaume Català, Paul T. Finger, Elena Kotova, Ashwin Mallipatna, Junyang Zhao, Winnie W. Y. Lau, Genoveva Correa-Llano, Tatiana L Ushakova, Ankit Singh Tomar, Jason C. S. Yam, Lorna Renner, Yacoub A. Yousef, Jonathan W. Kim, Elizabeth Esparza-Aguiar, Andrey A. Yarovoy, Vikas Khetan, Matthew W. Wilson, Sonia Moorthy, Marco A. Ramirez-Ortiz, and Chengyue Zhang

Subjects
Retinoblastoma, business.industry, Measures of national income and output, Treatment outcome, Outcome measures, Patient survival, World population, medicine.disease, Treatment failure, 3. Good health, 03 medical and health sciences, Ophthalmology, 0302 clinical medicine, 030220 oncology & carcinogenesis, 030221 ophthalmology & optometry, medicine, business, Demography, Cancer staging
Abstract

Purpose To compare metastasis-related mortality, local treatment failure, and globe salvage after retinoblastoma in countries with different national income levels. Design International, multicenter, registry-based retrospective case series. Participants Two thousand one hundred ninety patients, 18 ophthalmic oncology centers, and 13 countries on 6 continents. Methods Multicenter registry-based data were pooled from retinoblastoma patients enrolled between January 2001 and December 2013. Adequate data to allow American Joint Committee on Cancer staging, eighth edition, and analysis for the main outcome measures were available for 2085 patients. Each country was classified by national income level, as defined by the 2017 United Nations World Population Prospects, and included high-income countries (HICs), upper middle-income countries (UMICs), and lower middle-income countries (LMICs). Patient survival was estimated with the Kaplan-Meier method. Logistic and Cox proportional hazards regression models were used to determine associations between national income and treatment outcomes. Main Outcome Measures Metastasis-related mortality and local treatment failure (defined as use of secondary enucleation or external beam radiation therapy). Results Most (60%) study patients resided in UMICs and LMICs. The global median age at diagnosis was 17.0 months and higher in UMICs (20.0 months) and LMICs (20.0 months) than HICs (14.0 months; P Conclusions This international, multicenter, registry-based analysis of retinoblastoma management revealed that lower national income levels were associated with significantly higher rates of metastasis-related mortality, local treatment failure, and lower globe salvage.

Published
2021

13. Evaluation of prognostic risk models for postoperative pulmonary complications in adult patients undergoing major abdominal surgery: a systematic review and international external validation cohort study

Author

Kouli, O, primary, Murray, V, additional, Bhatia, S, additional, Cambridge, WA, additional, Kawka, M, additional, Shafi, S, additional, Knight, SR, additional, Kamarajah, SK, additional, McLean, KA, additional, Glasbey, JC, additional, Khaw, RA, additional, Ahmed, W, additional, Akhbari, M, additional, Baker, D, additional, Borakati, A, additional, Mills, E, additional, Thavayogan, R, additional, Yasin, I, additional, Raubenheimer, K, additional, Ridley, W, additional, Sarrami, M, additional, Zhang, G, additional, Egoroff, N, additional, Pockney, P, additional, Richards, T, additional, Bhangu, A, additional, Creagh-Brown, B, additional, Edwards, M, additional, Harrison, EM, additional, Lee, M, additional, Nepogodiev, D, additional, Pinkney, T, additional, Pearse, R, additional, Smart, N, additional, Vohra, R, additional, Sohrabi, C, additional, Jamieson, A, additional, Nguyen, M, additional, Rahman, A, additional, English, C, additional, Tincknell, L, additional, Kakodkar, P, additional, Kwek, I, additional, Punjabi, N, additional, Burns, J, additional, Varghese, S, additional, Erotocritou, M, additional, McGuckin, S, additional, Vayalapra, S, additional, Dominguez, E, additional, Moneim, J, additional, Salehi, M, additional, Tan, HL, additional, Yoong, A, additional, Zhu, L, additional, Seale, B, additional, Nowinka, Z, additional, Patel, N, additional, Chrisp, B, additional, Harris, J, additional, Maleyko, I, additional, Muneeb, F, additional, Gough, M, additional, James, CE, additional, Skan, O, additional, Chowdhury, A, additional, Rebuffa, N, additional, Khan, H, additional, Down, B, additional, Fatimah Hussain, Q, additional, Adams, M, additional, Bailey, A, additional, Cullen, G, additional, Fu, YXJ, additional, McClement, B, additional, Taylor, A, additional, Aitken, S, additional, Bachelet, B, additional, Brousse de Gersigny, J, additional, Chang, C, additional, Khehra, B, additional, Lahoud, N, additional, Lee Solano, M, additional, Louca, M, additional, Rozenbroek, P, additional, Rozitis, E, additional, Agbinya, N, additional, Anderson, E, additional, Arwi, G, additional, Barry, I, additional, Batchelor, C, additional, Chong, T, additional, Choo, LY, additional, Clark, L, additional, Daniels, M, additional, Goh, J, additional, Handa, A, additional, Hanna, J, additional, Huynh, L, additional, Jeon, A, additional, Kanbour, A, additional, Lee, A, additional, Lee, J, additional, Lee, T, additional, Leigh, J, additional, Ly, D, additional, McGregor, F, additional, Moss, J, additional, Nejatian, M, additional, O'Loughlin, E, additional, Ramos, I, additional, Sanchez, B, additional, Shrivathsa, A, additional, Sincari, A, additional, Sobhi, S, additional, Swart, R, additional, Trimboli, J, additional, Wignall, P, additional, Bourke, E, additional, Chong, A, additional, Clayton, S, additional, Dawson, A, additional, Hardy, E, additional, Iqbal, R, additional, Le, L, additional, Mao, S, additional, Marinelli, I, additional, Metcalfe, H, additional, Panicker, D, additional, R, HH, additional, Ridgway, S, additional, Tan, HH, additional, Thong, S, additional, Van, M, additional, Woon, S, additional, Woon-Shoo-Tong, XS, additional, Yu, S, additional, Ali, K, additional, Chee, J, additional, Chiu, C, additional, Chow, YW, additional, Duller, A, additional, Nagappan, P, additional, Ng, S, additional, Selvanathan, M, additional, Sheridan, C, additional, Temple, M, additional, Do, JE, additional, Dudi-Venkata, NN, additional, Humphries, E, additional, Li, L, additional, Mansour, LT, additional, Massy-Westropp, C, additional, Fang, B, additional, Farbood, K, additional, Hong, H, additional, Huang, Y, additional, Joan, M, additional, Koh, C, additional, Liu, YHA, additional, Mahajan, T, additional, Muller, E, additional, Park, R, additional, Tanudisastro, M, additional, Wu, JJG, additional, Chopra, P, additional, Giang, S, additional, Radcliffe, S, additional, Thach, P, additional, Wallace, D, additional, Wilkes, A, additional, Chinta, SH, additional, Li, J, additional, Phan, J, additional, Rahman, F, additional, Segaran, A, additional, Shannon, J, additional, Zhang, M, additional, Adams, N, additional, Bonte, A, additional, Choudhry, A, additional, Colterjohn, N, additional, Croyle, JA, additional, Donohue, J, additional, Feighery, A, additional, Keane, A, additional, McNamara, D, additional, Munir, K, additional, Roche, D, additional, Sabnani, R, additional, Seligman, D, additional, Sharma, S, additional, Stickney, Z, additional, Suchy, H, additional, Tan, R, additional, Yordi, S, additional, Ahmed, I, additional, Aranha, M, additional, El Sabawy, D, additional, Garwood, P, additional, Harnett, M, additional, Holohan, R, additional, Howard, R, additional, Kayyal, Y, additional, Krakoski, N, additional, Lupo, M, additional, McGilberry, W, additional, Nepon, H, additional, Scoleri, Y, additional, Urbina, C, additional, Ahmad Fuad, MF, additional, Ahmed, O, additional, Jaswantlal, D, additional, Kelly, E, additional, Khan, MHT, additional, Naidu, D, additional, Neo, WX, additional, O'Neill, R, additional, Sugrue, M, additional, Abbas, JD, additional, Abdul-Fattah, S, additional, Azlan, A, additional, Barry, K, additional, Idris, NS, additional, Kaka, N, additional, Mc Dermott, D, additional, Mohammad Nasir, MN, additional, Mozo, M, additional, Rehal, A, additional, Shaikh Yousef, M, additional, Wong, RH, additional, Curran, E, additional, Gardner, M, additional, Hogan, A, additional, Julka, R, additional, Lasser, G, additional, Ní Chorráin, N, additional, Ting, J, additional, Browne, R, additional, George, S, additional, Janjua, Z, additional, Leung Shing, V, additional, Megally, M, additional, Murphy, S, additional, Ravenscroft, L, additional, Vedadi, A, additional, Vyas, V, additional, Bryan, A, additional, Sheikh, A, additional, Ubhi, J, additional, Vannelli, K, additional, Vawda, A, additional, Adeusi, L, additional, Doherty, C, additional, Fitzgerald, C, additional, Gallagher, H, additional, Gill, P, additional, Hamza, H, additional, Hogan, M, additional, Kelly, S, additional, Larry, J, additional, Lynch, P, additional, Mazeni, NA, additional, O'Connell, R, additional, O'Loghlin, R, additional, Singh, K, additional, Abbas Syed, R, additional, Ali, A, additional, Alkandari, B, additional, Arnold, A, additional, Arora, E, additional, Azam, R, additional, Breathnach, C, additional, Cheema, J, additional, Compton, M, additional, Curran, S, additional, Elliott, JA, additional, Jayasamraj, O, additional, Mohammed, N, additional, Noone, A, additional, Pal, A, additional, Pandey, S, additional, Quinn, P, additional, Sheridan, R, additional, Siew, L, additional, Tan, EP, additional, Tio, SW, additional, Toh, VTR, additional, Walsh, M, additional, Yap, C, additional, Yassa, J, additional, Young, T, additional, Agarwal, N, additional, Almoosawy, SA, additional, Bowen, K, additional, Bruce, D, additional, Connachan, R, additional, Cook, A, additional, Daniell, A, additional, Elliott, M, additional, Fung, HKF, additional, Irving, A, additional, Laurie, S, additional, Lee, YJ, additional, Lim, ZX, additional, Maddineni, S, additional, McClenaghan, RE, additional, Muthuganesan, V, additional, Ravichandran, P, additional, Roberts, N, additional, Shaji, S, additional, Solt, S, additional, Toshney, E, additional, Arnold, C, additional, Baker, O, additional, Belais, F, additional, Bojanic, C, additional, Byrne, M, additional, Chau, CYC, additional, De Soysa, S, additional, Eldridge, M, additional, Fairey, M, additional, Fearnhead, N, additional, Guéroult, A, additional, Ho, JSY, additional, Joshi, K, additional, Kadiyala, N, additional, Khalid, S, additional, Khan, F, additional, Kumar, K, additional, Lewis, E, additional, Magee, J, additional, Manetta-Jones, D, additional, Mann, S, additional, McKeown, L, additional, Mitrofan, C, additional, Mohamed, T, additional, Monnickendam, A, additional, Ng, AYKC, additional, Ortu, A, additional, Patel, M, additional, Pope, T, additional, Pressling, S, additional, Purohit, K, additional, Saji, S, additional, Shah Foridi, J, additional, Shah, R, additional, Siddiqui, SS, additional, Surman, K, additional, Utukuri, M, additional, Varghese, A, additional, Williams, CYK, additional, Yang, JJ, additional, Billson, E, additional, Cheah, E, additional, Holmes, P, additional, Hussain, S, additional, Murdock, D, additional, Nicholls, A, additional, Patel, P, additional, Ramana, G, additional, Saleki, M, additional, Spence, H, additional, Thomas, D, additional, Yu, C, additional, Abousamra, M, additional, Brown, C, additional, Conti, I, additional, Donnelly, A, additional, Durand, M, additional, French, N, additional, Goan, R, additional, O'Kane, E, additional, Rubinchik, P, additional, Gardiner, H, additional, Kempf, B, additional, Lai, YL, additional, Matthews, H, additional, Minford, E, additional, Rafferty, C, additional, Reid, C, additional, Sheridan, N, additional, Al Bahri, T, additional, Bhoombla, N, additional, Rao, BM, additional, Titu, L, additional, Chatha, S, additional, Field, C, additional, Gandhi, T, additional, Gulati, R, additional, Jha, R, additional, Jones Sam, MT, additional, Karim, S, additional, Patel, R, additional, Saunders, M, additional, Sharma, K, additional, Abid, S, additional, Heath, E, additional, Kurup, D, additional, Patel, A, additional, Ali, M, additional, Cresswell, B, additional, Felstead, D, additional, Jennings, K, additional, Kaluarachchi, T, additional, Lazzereschi, L, additional, Mayson, H, additional, Miah, JE, additional, Reinders, B, additional, Rosser, A, additional, Thomas, C, additional, Williams, H, additional, Al-Hamid, Z, additional, Alsadoun, L, additional, Chlubek, M, additional, Fernando, P, additional, Gaunt, E, additional, Gercek, Y, additional, Maniar, R, additional, Ma, R, additional, Matson, M, additional, Moore, S, additional, Morris, A, additional, Nagappan, PG, additional, Ratnayake, M, additional, Rockall, L, additional, Shallcross, O, additional, Sinha, A, additional, Tan, KE, additional, Virdee, S, additional, Wenlock, R, additional, Donnelly, HA, additional, Ghazal, R, additional, Hughes, I, additional, Liu, X, additional, McFadden, M, additional, Misbert, E, additional, Mogey, P, additional, O'Hara, A, additional, Peace, C, additional, Rainey, C, additional, Raja, P, additional, Salem, M, additional, Salmon, J, additional, Tan, CH, additional, Alves, D, additional, Bahl, S, additional, Baker, C, additional, Coulthurst, J, additional, Koysombat, K, additional, Linn, T, additional, Rai, P, additional, Sharma, A, additional, Shergill, A, additional, Ahmed, M, additional, Ahmed, S, additional, Belk, LH, additional, Choudhry, H, additional, Cummings, D, additional, Dixon, Y, additional, Dobinson, C, additional, Edwards, J, additional, Flint, J, additional, Franco Da Silva, C, additional, Gallie, R, additional, Gardener, M, additional, Glover, T, additional, Greasley, M, additional, Hatab, A, additional, Howells, R, additional, Hussey, T, additional, Khan, A, additional, Mann, A, additional, Morrison, H, additional, Ng, A, additional, Osmond, R, additional, Padmakumar, N, additional, Pervaiz, F, additional, Prince, R, additional, Qureshi, A, additional, Sawhney, R, additional, Sigurdson, B, additional, Stephenson, L, additional, Vora, K, additional, Zacken, A, additional, Cope, P, additional, Di Traglia, R, additional, Ferarrio, I, additional, Hackett, N, additional, Healicon, R, additional, Horseman, L, additional, Lam, LI, additional, Meerdink, M, additional, Menham, D, additional, Murphy, R, additional, Nimmo, I, additional, Ramaesh, A, additional, Rees, J, additional, Soame, R, additional, Dilaver, N, additional, Adebambo, D, additional, Brown, E, additional, Burt, J, additional, Foster, K, additional, Kaliyappan, L, additional, Knight, P, additional, Politis, A, additional, Richardson, E, additional, Townsend, J, additional, Abdi, M, additional, Ball, M, additional, Easby, S, additional, Gill, N, additional, Ho, E, additional, Iqbal, H, additional, Matthews, M, additional, Nubi, S, additional, Nwokocha, JO, additional, Okafor, I, additional, Perry, G, additional, Sinartio, B, additional, Vanukuru, N, additional, Walkley, D, additional, Welch, T, additional, Yates, J, additional, Yeshitila, N, additional, Bryans, K, additional, Campbell, B, additional, Gray, C, additional, Keys, R, additional, Macartney, M, additional, Chamberlain, G, additional, Khatri, A, additional, Kucheria, A, additional, Lee, STP, additional, Reese, G, additional, Roy choudhury, J, additional, Tan, WYR, additional, Teh, JJ, additional, Ting, A, additional, Kazi, S, additional, Kontovounisios, C, additional, Vutipongsatorn, K, additional, Amarnath, T, additional, Balasubramanian, N, additional, Bassett, E, additional, Gurung, P, additional, Lim, J, additional, Panjikkaran, A, additional, Sanalla, A, additional, Alkoot, M, additional, Bacigalupo, V, additional, Eardley, N, additional, Horton, M, additional, Hurry, A, additional, Isti, C, additional, Maskell, P, additional, Nursiah, K, additional, Punn, G, additional, Salih, H, additional, Epanomeritakis, E, additional, Foulkes, A, additional, Henderson, R, additional, Johnston, E, additional, McCullough, H, additional, McLarnon, M, additional, Morrison, E, additional, Cheung, A, additional, Cho, SH, additional, Eriksson, F, additional, Hedges, J, additional, Low, Z, additional, May, C, additional, Musto, L, additional, Nagi, S, additional, Nur, S, additional, Salau, E, additional, Shabbir, S, additional, Thomas, MC, additional, Uthayanan, L, additional, Vig, S, additional, Zaheer, M, additional, Zeng, G, additional, Ashcroft-Quinn, S, additional, Brown, R, additional, Hayes, J, additional, McConville, R, additional, French, R, additional, Gilliam, A, additional, Sheetal, S, additional, Shehzad, MU, additional, Bani, W, additional, Christie, I, additional, Franklyn, J, additional, Khan, M, additional, Russell, J, additional, Smolarek, S, additional, Varadarassou, R, additional, Ahmed, SK, additional, Narayanaswamy, S, additional, Sealy, J, additional, Shah, M, additional, Dodhia, V, additional, Manukyan, A, additional, O'Hare, R, additional, Orbell, J, additional, Chung, I, additional, Forenc, K, additional, Gupta, A, additional, Agarwal, A, additional, Al Dabbagh, A, additional, Bennewith, R, additional, Bottomley, J, additional, Chu, TSM, additional, Chu, YYA, additional, Doherty, W, additional, Evans, B, additional, Hainsworth, P, additional, Hosfield, T, additional, Li, CH, additional, McCullagh, I, additional, Mehta, A, additional, Thaker, A, additional, Thompson, B, additional, Virdi, A, additional, Walker, H, additional, Wilkins, E, additional, Dixon, C, additional, Hassan, MR, additional, Lotca, N, additional, Tong, KS, additional, Batchelor-Parry, H, additional, Chaudhari, S, additional, Harris, T, additional, Hooper, J, additional, Johnson, C, additional, Mulvihill, C, additional, Nayler, J, additional, Olutobi, O, additional, Piramanayagam, B, additional, Stones, K, additional, Sussman, M, additional, Weaver, C, additional, Alam, F, additional, Al Rawi, M, additional, Andrew, F, additional, Arrayeh, A, additional, Azizan, N, additional, Hassan, A, additional, Iqbal, Z, additional, John, I, additional, Jones, M, additional, Kalake, O, additional, Keast, M, additional, Nicholas, J, additional, Patil, A, additional, Powell, K, additional, Roberts, P, additional, Sabri, A, additional, Segue, AK, additional, Shah, A, additional, Shaik Mohamed, SA, additional, Shehadeh, A, additional, Shenoy, S, additional, Tong, A, additional, Upcott, M, additional, Vijayasingam, D, additional, Anarfi, S, additional, Dauncey, J, additional, Devindaran, A, additional, Havalda, P, additional, Komninos, G, additional, Mwendwa, E, additional, Norman, C, additional, Richards, J, additional, Urquhart, A, additional, Allan, J, additional, Cahya, E, additional, Hunt, H, additional, McWhirter, C, additional, Norton, R, additional, Roxburgh, C, additional, Tan, JY, additional, Ali Butt, S, additional, Hansdot, S, additional, Haq, I, additional, Mootien, A, additional, Sanchez, I, additional, Vainas, T, additional, Deliyannis, E, additional, Tan, M, additional, Vipond, M, additional, Chittoor Satish, NN, additional, Dattani, A, additional, De Carvalho, L, additional, Gaston-Grubb, M, additional, Karunanithy, L, additional, Lowe, B, additional, Pace, C, additional, Raju, K, additional, Roope, J, additional, Taylor, C, additional, Youssef, H, additional, Munro, T, additional, Thorn, C, additional, Wong, KHF, additional, Yunus, A, additional, Chawla, S, additional, Datta, A, additional, Dinesh, AA, additional, Field, D, additional, Georgi, T, additional, Gwozdz, A, additional, Hamstead, E, additional, Howard, N, additional, Isleyen, N, additional, Jackson, N, additional, Kingdon, J, additional, Sagoo, KS, additional, Schizas, A, additional, Yin, L, additional, Aung, E, additional, Aung, YY, additional, Franklin, S, additional, Han, SM, additional, Kim, WC, additional, Martin Segura, A, additional, Rossi, M, additional, Ross, T, additional, Tirimanna, R, additional, Wang, B, additional, Zakieh, O, additional, Ben-Arzi, H, additional, Flach, A, additional, Jackson, E, additional, Magers, S, additional, Olu abara, C, additional, Rogers, E, additional, Sugden, K, additional, Tan, H, additional, Veliah, S, additional, Walton, U, additional, Asif, A, additional, Bharwada, Y, additional, Bowley, D, additional, Broekhuizen, A, additional, Cooper, L, additional, Evans, N, additional, Girdlestone, H, additional, Ling, C, additional, Mann, H, additional, Mehmood, N, additional, Mulvenna, CL, additional, Rainer, N, additional, Trout, I, additional, Gujjuri, R, additional, Jeyaraman, D, additional, Leong, E, additional, Singh, D, additional, Smith, E, additional, Anderton, J, additional, Barabas, M, additional, Goyal, S, additional, Howard, D, additional, Joshi, A, additional, Mitchell, D, additional, Weatherby, T, additional, Badminton, R, additional, Bird, R, additional, Burtle, D, additional, Choi, NY, additional, Devalia, K, additional, Farr, E, additional, Fischer, F, additional, Fish, J, additional, Gunn, F, additional, Jacobs, D, additional, Johnston, P, additional, Kalakoutas, A, additional, Lau, E, additional, Loo, YNAF, additional, Louden, H, additional, Makariou, N, additional, Mohammadi, K, additional, Nayab, Y, additional, Ruhomaun, S, additional, Ryliskyte, R, additional, Saeed, M, additional, Shinde, P, additional, Sudul, M, additional, Theodoropoulou, K, additional, Valadao-Spoorenberg, J, additional, Vlachou, F, additional, Arshad, SR, additional, Janmohamed, AM, additional, Noor, M, additional, Oyerinde, O, additional, Saha, A, additional, Syed, Y, additional, Watkinson, W, additional, Ahmadi, H, additional, Akintunde, A, additional, Alsaady, A, additional, Bradley, J, additional, Brothwood, D, additional, Burton, M, additional, Higgs, M, additional, Hoyle, C, additional, Katsura, C, additional, Lathan, R, additional, Louani, A, additional, Mandalia, R, additional, Prihartadi, AS, additional, Qaddoura, B, additional, Sandland-Taylor, L, additional, Thadani, S, additional, Thompson, A, additional, Walshaw, J, additional, Teo, S, additional, Ali, S, additional, Bawa, JH, additional, Fox, S, additional, Gargan, K, additional, Haider, SA, additional, Hanna, N, additional, Hatoum, A, additional, Khan, Z, additional, Krzak, AM, additional, Li, T, additional, Pitt, J, additional, Tan, GJS, additional, Ullah, Z, additional, Wilson, E, additional, Cleaver, J, additional, Colman, J, additional, Copeland, L, additional, Coulson, A, additional, Davis, P, additional, Faisal, H, additional, Hassan, F, additional, Hughes, JT, additional, Jabr, Y, additional, Mahmoud Ali, F, additional, Nahaboo Solim, ZN, additional, Sangheli, A, additional, Shaya, S, additional, Thompson, R, additional, Cornwall, H, additional, De Andres Crespo, M, additional, Fay, E, additional, Findlay, J, additional, Groves, E, additional, Jones, O, additional, Killen, A, additional, Millo, J, additional, Thomas, S, additional, Ward, J, additional, Wilkins, M, additional, Zaki, F, additional, Zilber, E, additional, Bhavra, K, additional, Bilolikar, A, additional, Charalambous, M, additional, Elawad, A, additional, Eleni, A, additional, Fawdon, R, additional, Gibbins, A, additional, Livingstone, D, additional, Mala, D, additional, Oke, SE, additional, Padmakumar, D, additional, Patsalides, MA, additional, Payne, D, additional, Ralphs, C, additional, Roney, A, additional, Sardar, N, additional, Stefanova, K, additional, Surti, F, additional, Timms, R, additional, Tosney, G, additional, Bannister, J, additional, Clement, NS, additional, Cullimore, V, additional, Kamal, F, additional, Lendor, J, additional, McKay, J, additional, Mcswiggan, J, additional, Minhas, N, additional, Seneviratne, K, additional, Simeen, S, additional, Valverde, J, additional, Watson, N, additional, Bloom, I, additional, Dinh, TH, additional, Hirniak, J, additional, Joseph, R, additional, Kansagra, M, additional, Lai, CKN, additional, Melamed, N, additional, Patel, J, additional, Randev, J, additional, Sedighi, T, additional, Shurovi, B, additional, Sodhi, J, additional, Vadgama, N, additional, Abdulla, S, additional, Adabavazeh, B, additional, Champion, A, additional, Chennupati, R, additional, Chu, K, additional, Devi, S, additional, Haji, A, additional, Schulz, J, additional, Testa, F, additional, Davies, P, additional, Gurung, B, additional, Howell, S, additional, Modi, P, additional, Pervaiz, A, additional, Zahid, M, additional, Abdolrazaghi, S, additional, Abi Aoun, R, additional, Anjum, Z, additional, Bawa, G, additional, Bhardwaj, R, additional, Brown, S, additional, Enver, M, additional, Gill, D, additional, Gopikrishna, D, additional, Gurung, D, additional, Kanwal, A, additional, Kaushal, P, additional, Khanna, A, additional, Lovell, E, additional, McEvoy, C, additional, Mirza, M, additional, Nabeel, S, additional, Naseem, S, additional, Pandya, K, additional, Perkins, R, additional, Pulakal, R, additional, Ray, M, additional, Reay, C, additional, Reilly, S, additional, Round, A, additional, Seehra, J, additional, Shakeel, NM, additional, Singh, B, additional, Vijay Sukhnani, M, additional, Brown, L, additional, Desai, B, additional, Elzanati, H, additional, Godhaniya, J, additional, Kavanagh, E, additional, Kent, J, additional, Kishor, A, additional, Liu, A, additional, Norwood, M, additional, Shaari, N, additional, Wood, C, additional, Wood, M, additional, Brown, A, additional, Chellapuri, A, additional, Ferriman, A, additional, Ghosh, I, additional, Kulkarni, N, additional, Noton, T, additional, Pinto, A, additional, Rajesh, S, additional, Varghese, B, additional, Wenban, C, additional, Aly, R, additional, Barciela, C, additional, Brookes, T, additional, Corrin, E, additional, Goldsworthy, M, additional, Mohamed Azhar, MS, additional, Moore, J, additional, Nakhuda, S, additional, Ng, D, additional, Pillay, S, additional, Port, S, additional, Abdullah, M, additional, Akinyemi, J, additional, Islam, S, additional, Kale, A, additional, Lewis, A, additional, Manjunath, T, additional, McCabe, H, additional, Misra, S, additional, Stubley, T, additional, Tam, JP, additional, Waraich, N, additional, Chaora, T, additional, Ford, C, additional, Osinkolu, I, additional, Pong, G, additional, Rai, J, additional, Risquet, R, additional, Ainsworth, J, additional, Ayandokun, P, additional, Barham, E, additional, Barrett, G, additional, Barry, J, additional, Bisson, E, additional, Bridges, I, additional, Burke, D, additional, Cann, J, additional, Cloney, M, additional, Coates, S, additional, Cripps, P, additional, Davies, C, additional, Francis, N, additional, Green, S, additional, Handley, G, additional, Hathaway, D, additional, Hurt, L, additional, Jenkins, S, additional, Johnston, C, additional, Khadka, A, additional, McGee, U, additional, Morris, D, additional, Murray, R, additional, Norbury, C, additional, Pierrepont, Z, additional, Richards, C, additional, Ross, O, additional, Ruddy, A, additional, Salmon, C, additional, Shield, M, additional, Soanes, K, additional, Spencer, N, additional, Taverner, S, additional, Williams, C, additional, Wills-Wood, W, additional, Woodward, S, additional, Chow, J, additional, Fan, J, additional, Guest, O, additional, Hunter, I, additional, Moon, WY, additional, Arthur-Quarm, S, additional, Edwards, P, additional, Hamlyn, V, additional, McEneaney, L, additional, N D, G, additional, Pranoy, S, additional, Ting, M, additional, Abada, S, additional, Alawattegama, LH, additional, Ashok, A, additional, Carey, C, additional, Gogna, A, additional, Haglund, C, additional, Hurley, P, additional, Leelo, N, additional, Liu, B, additional, Mannan, F, additional, Paramjothy, K, additional, Ramlogan, K, additional, Raymond-Hayling, O, additional, Shanmugarajah, A, additional, Solichan, D, additional, Wilkinson, B, additional, Ahmad, NA, additional, Allan, D, additional, Amin, A, additional, Bakina, C, additional, Burns, F, additional, Cameron, F, additional, Campbell, A, additional, Cavanagh, S, additional, Chan, SMZ, additional, Chapman, S, additional, Chong, V, additional, Edelsten, E, additional, Ekpete, O, additional, El Sheikh, M, additional, Ghose, R, additional, Hassane, A, additional, Henderson, C, additional, Hilton-Christie, S, additional, Husain, M, additional, Hussain, H, additional, Javid, Z, additional, Johnson-Ogbuneke, J, additional, Johnston, A, additional, Khalil, M, additional, Leung, TCC, additional, Makin, I, additional, Muralidharan, V, additional, Naeem, M, additional, Patil, P, additional, Ravichandran, S, additional, Saraeva, D, additional, Shankey-Smith, W, additional, Sharma, N, additional, Swan, R, additional, Waudby-West, R, additional, Wilkinson, A, additional, Wright, K, additional, Balasubramanian, A, additional, Bhatti, S, additional, Chalkley, M, additional, Chou, WK, additional, Dixon, M, additional, Evans, L, additional, Fisher, K, additional, Gandhi, P, additional, Ho, S, additional, Lau, YB, additional, Lowe, S, additional, Meechan, C, additional, Murali, N, additional, Musonda, C, additional, Njoku, P, additional, Ochieng, L, additional, Pervez, MU, additional, Seebah, K, additional, Shaikh, I, additional, Sikder, MA, additional, Vanker, R, additional, Alom, J, additional, Bajaj, V, additional, Coleman, O, additional, Finch, G, additional, Goss, J, additional, Jenkins, C, additional, Kontothanassis, A, additional, Liew, MS, additional, Ng, K, additional, Outram, M, additional, Shakeel, MM, additional, Tawn, J, additional, Zuhairy, S, additional, Chapple, K, additional, Cinnamond, A, additional, Coleman, S, additional, George, HA, additional, Goulder, L, additional, Hare, N, additional, Hawksley, J, additional, Kret, A, additional, Luesley, A, additional, Mecia, L, additional, Porter, H, additional, Puddy, E, additional, Richardson, G, additional, Sohail, B, additional, Srikaran, V, additional, Tadross, D, additional, Tobin, J, additional, Tokidis, E, additional, Young, L, additional, Ashdown, T, additional, Bratsos, S, additional, Koomson, A, additional, Kufuor, A, additional, Lim, MQ, additional, Shah, S, additional, Thorne, EPC, additional, Warusavitarne, J, additional, Xu, S, additional, Abigail, S, additional, Ahmed, A, additional, Ahmed, J, additional, Akmal, A, additional, Al-Khafaji, M, additional, Amini, B, additional, Arshad, M, additional, Bogie, E, additional, Brazkiewicz, M, additional, Carroll, M, additional, Chandegra, A, additional, Cirelli, C, additional, Deng, A, additional, Fairclough, S, additional, Fung, YJ, additional, Gornell, C, additional, Green, RL, additional, Green, SV, additional, Gulamhussein, AHM, additional, Isaac, AG, additional, Jan, R, additional, Jegatheeswaran, L, additional, Knee, M, additional, Kotecha, J, additional, Kotecha, S, additional, Maxwell-Armstrong, C, additional, McIntyre, C, additional, Mendis, N, additional, Naing, TKP, additional, Oberman, J, additional, Ong, ZX, additional, Ramalingam, A, additional, Saeed Adam, A, additional, Tan, LL, additional, Towell, S, additional, Yadav, J, additional, Anandampillai, R, additional, Chung, S, additional, Hounat, A, additional, Ibrahim, B, additional, Jeyakumar, G, additional, Khalil, A, additional, Khan, UA, additional, Nair, G, additional, Owusu-Ayim, M, additional, Wilson, M, additional, Kanani, A, additional, Kilkelly, B, additional, Ogunmwonyi, I, additional, Ong, L, additional, Samra, B, additional, Schomerus, L, additional, Shea, J, additional, Turner, O, additional, Yang, Y, additional, Amin, M, additional, Blott, N, additional, Clark, A, additional, Feather, A, additional, Forrest, M, additional, Hague, S, additional, Hamilton, K, additional, Higginbotham, G, additional, Hope, E, additional, Karimian, S, additional, Loveday, K, additional, Malik, H, additional, McKenna, O, additional, Noor, A, additional, Onsiong, C, additional, Patel, B, additional, Radcliffe, N, additional, Shah, P, additional, Tye, L, additional, Verma, K, additional, Walford, R, additional, Yusufi, U, additional, Zachariah, M, additional, Casey, A, additional, Doré, C, additional, Fludder, V, additional, Fortescue, L, additional, Kalapu, SS, additional, Karel, E, additional, Khera, G, additional, Smith, C, additional, Appleton, B, additional, Ashaye, A, additional, Boggon, E, additional, Evans, A, additional, Faris Mahmood, H, additional, Hinchcliffe, Z, additional, Marei, O, additional, Silva, I, additional, Spooner, C, additional, Thomas, G, additional, Timlin, M, additional, Wellington, J, additional, Yao, SL, additional, Abdelrazek, M, additional, Abdelrazik, Y, additional, Bee, F, additional, Joseph, A, additional, Mounce, A, additional, Parry, G, additional, Vignarajah, N, additional, Biddles, D, additional, Creissen, A, additional, Kolhe, S, additional, K, T, additional, Lea, A, additional, Ledda, V, additional, O'Loughlin, P, additional, Scanlon, J, additional, Shetty, N, additional, Weller, C, additional, Abdalla, M, additional, Adeoye, A, additional, Bhatti, M, additional, Chadda, KR, additional, Chu, J, additional, Elhakim, H, additional, Foster-Davies, H, additional, Rabie, M, additional, Tailor, B, additional, Webb, S, additional, Abdelrahim, ASA, additional, Choo, SY, additional, Jiwa, A, additional, Mangam, S, additional, Murray, S, additional, Shandramohan, A, additional, Aghanenu, O, additional, Budd, W, additional, Hayre, J, additional, Khanom, S, additional, Liew, ZY, additional, McKinney, R, additional, Moody, N, additional, Muhammad-Kamal, H, additional, Odogwu, J, additional, Patel, D, additional, Roy, C, additional, Sattar, Z, additional, Shahrokhi, N, additional, Sinha, I, additional, Thomson, E, additional, Wonga, L, additional, Bain, J, additional, Khan, J, additional, Ricardo, D, additional, Bevis, R, additional, Cherry, C, additional, Darkwa, S, additional, Drew, W, additional, Griffiths, E, additional, Konda, N, additional, Madani, D, additional, Mak, JKC, additional, Meda, B, additional, Odunukwe, U, additional, Preest, G, additional, Raheel, F, additional, Rajaseharan, A, additional, Ramgopal, A, additional, Risbrooke, C, additional, Selvaratnam, K, additional, Sethunath, G, additional, Tabassum, R, additional, Taylor, J, additional, Thakker, A, additional, Wijesingha, N, additional, Wybrew, R, additional, Yasin, T, additional, Ahmed Osman, A, additional, Alfadhel, S, additional, Carberry, E, additional, Chen, JY, additional, Drake, I, additional, Glen, P, additional, Jayasuriya, N, additional, Kawar, L, additional, Myatt, R, additional, Sinan, LOH, additional, Siu, SSY, additional, Tjen, V, additional, Adeboyejo, O, additional, Bacon, H, additional, Barnes, R, additional, Birnie, C, additional, D'Cunha Kamath, A, additional, Hughes, E, additional, Middleton, S, additional, Owen, R, additional, Schofield, E, additional, Short, C, additional, Smith, R, additional, Wang, H, additional, Willett, M, additional, Zimmerman, M, additional, Balfour, J, additional, Chadwick, T, additional, Coombe-Jones, M, additional, Do Le, HP, additional, Faulkner, G, additional, Hobson, K, additional, Shehata, Z, additional, Beattie, M, additional, Chmielewski, G, additional, Chong, C, additional, Donnelly, B, additional, Drusch, B, additional, Ellis, J, additional, Farrelly, C, additional, Feyi-Waboso, J, additional, Hibell, I, additional, Hoade, L, additional, Ho, C, additional, Jones, H, additional, Kodiatt, B, additional, Lidder, P, additional, Ni Cheallaigh, L, additional, Norman, R, additional, Patabendi, I, additional, Penfold, H, additional, Playfair, M, additional, Pomeroy, S, additional, Ralph, C, additional, Rottenburg, H, additional, Sebastian, J, additional, Sheehan, M, additional, Stanley, V, additional, Welchman, J, additional, Ajdarpasic, D, additional, Antypas, A, additional, Azouaghe, O, additional, Basi, S, additional, Bettoli, G, additional, Bhattarai, S, additional, Bommireddy, L, additional, Bourne, K, additional, Budding, J, additional, Cookey-Bresi, R, additional, Cummins, T, additional, Davies, G, additional, Fabelurin, C, additional, Gwilliam, R, additional, Hanley, J, additional, Hird, A, additional, Kruczynska, A, additional, Langhorne, B, additional, Lund, J, additional, Lutchman, I, additional, McGuinness, R, additional, Neary, M, additional, Pampapathi, S, additional, Pang, E, additional, Podbicanin, S, additional, Rai, N, additional, Redhouse White, G, additional, Sujith, J, additional, Thomas, P, additional, Walker, I, additional, Winterton, R, additional, Anderson, P, additional, Barrington, M, additional, Bhadra, K, additional, Clark, G, additional, Fowler, G, additional, Gibson, C, additional, Hudson, S, additional, Kaminskaite, V, additional, Lawday, S, additional, Longshaw, A, additional, MacKrill, E, additional, McLachlan, F, additional, Murdeshwar, A, additional, Nieuwoudt, R, additional, Parker, P, additional, Randall, R, additional, Rawlins, E, additional, Reeves, SA, additional, Rye, D, additional, Sirkis, T, additional, Sykes, B, additional, Ventress, N, additional, Wosinska, N, additional, Akram, B, additional, Burton, L, additional, Coombs, A, additional, Long, R, additional, Magowan, D, additional, Ong, C, additional, Sethi, M, additional, Williams, G, additional, Chan, C, additional, Chan, LH, additional, Fernando, D, additional, Gaba, F, additional, Khor, Z, additional, Les, JW, additional, Mak, R, additional, Moin, S, additional, Ng Kee Kwong, KC, additional, Paterson-Brown, S, additional, Tew, YY, additional, Bardon, A, additional, Burrell, K, additional, Coldwell, C, additional, Costa, I, additional, Dexter, E, additional, Hardy, A, additional, Khojani, M, additional, Mazurek, J, additional, Raymond, T, additional, Reddy, V, additional, Reynolds, J, additional, Soma, A, additional, Agiotakis, S, additional, Alsusa, H, additional, Desai, N, additional, Peristerakis, I, additional, Adcock, A, additional, Ayub, H, additional, Bennett, T, additional, Bibi, F, additional, Brenac, S, additional, Chapman, T, additional, Clarke, G, additional, Clark, F, additional, Galvin, C, additional, Gwyn-Jones, A, additional, Henry-Blake, C, additional, Kerner, S, additional, Kiandee, M, additional, Lovett, A, additional, Pilecka, A, additional, Ravindran, R, additional, Siddique, H, additional, Sikand, T, additional, Treadwell, K, additional, Akmal, K, additional, Apata, A, additional, Barton, O, additional, Broad, G, additional, Darling, H, additional, Dhuga, Y, additional, Emms, L, additional, Habib, S, additional, Jain, R, additional, Jeater, J, additional, Kan, CYP, additional, Kathiravelupillai, A, additional, Khatkar, H, additional, Kirmani, S, additional, Kulasabanathan, K, additional, Lacey, H, additional, Lal, K, additional, Manafa, C, additional, Mansoor, M, additional, McDonald, S, additional, Mittal, A, additional, Mustoe, S, additional, Nottrodt, L, additional, Oliver, P, additional, Papapetrou, I, additional, Pattinson, F, additional, Raja, M, additional, Reyhani, H, additional, Shahmiri, A, additional, Small, O, additional, Soni, U, additional, Aguirrezabala Armbruster, B, additional, Bunni, J, additional, Hakim, MA, additional, Hawkins-Hooker, L, additional, Howell, KA, additional, Hullait, R, additional, Jaskowska, A, additional, Ottewell, L, additional, Thomas-Jones, I, additional, Vasudev, A, additional, Clements, B, additional, Fenton, J, additional, Gill, M, additional, Haider, S, additional, Lim, AJM, additional, Maguire, H, additional, McMullan, J, additional, Nicoletti, J, additional, Samuel, S, additional, Unais, MA, additional, White, N, additional, Yao, PC, additional, Yow, L, additional, Boyle, C, additional, Brady, R, additional, Cheekoty, P, additional, Cheong, J, additional, Chew, SJHL, additional, Chow, R, additional, Ganewatta Kankanamge, D, additional, Mamer, L, additional, Mohammed, B, additional, Ng Chieng Hin, J, additional, Renji Chungath, R, additional, Royston, A, additional, Sharrad, E, additional, Sinclair, R, additional, Tingle, S, additional, Treherne, K, additional, Wyatt, F, additional, Maniarasu, VS, additional, Moug, S, additional, Appanna, T, additional, Bucknall, T, additional, Hussain, F, additional, Owen, A, additional, Parry, M, additional, Parry, R, additional, Sagua, N, additional, Spofforth, K, additional, Yuen, ECT, additional, Bosley, N, additional, Hardie, W, additional, Moore, T, additional, Regas, C, additional, Abdel-Khaleq, S, additional, Ali, N, additional, Bashiti, H, additional, Buxton-Hopley, R, additional, Constantinides, M, additional, D'Afflitto, M, additional, Deshpande, A, additional, Duque Golding, J, additional, Frisira, E, additional, Germani Batacchi, M, additional, Gomaa, A, additional, Hay, D, additional, Hutchison, R, additional, Iakovou, A, additional, Iakovou, D, additional, Ismail, E, additional, Jefferson, S, additional, Jones, L, additional, Khouli, Y, additional, Knowles, C, additional, Mason, J, additional, McCaughan, R, additional, Moffatt, J, additional, Morawala, A, additional, Nadir, H, additional, Neyroud, F, additional, Nikookam, Y, additional, Parmar, A, additional, Pinto, L, additional, Ramamoorthy, R, additional, Richards, E, additional, Thomson, S, additional, Trainer, C, additional, Valetopoulou, A, additional, Vassiliou, A, additional, Wantman, A, additional, Wilde, S, additional, Dickinson, M, additional, Rockall, T, additional, Senn, D, additional, Wcislo, K, additional, Zalmay, P, additional, Adelekan, K, additional, Allen, K, additional, Bajaj, M, additional, Gatumbu, P, additional, Hang, S, additional, Hashmi, Y, additional, Kaur, T, additional, Kawesha, A, additional, Kisiel, A, additional, Woodmass, M, additional, Adelowo, T, additional, Ahari, D, additional, Alhwaishel, K, additional, Atherton, R, additional, Clayton, B, additional, Cockroft, A, additional, Curtis Lopez, C, additional, Hilton, M, additional, Ismail, N, additional, Kouadria, M, additional, Lee, L, additional, MacConnachie, A, additional, Monks, F, additional, Mungroo, S, additional, Nikoletopoulou, C, additional, Pearce, L, additional, Sara, X, additional, Shahid, A, additional, Suresh, G, additional, Wilcha, R, additional, Atiyah, A, additional, Davies, E, additional, Dermanis, A, additional, Gibbons, H, additional, Hyde, A, additional, Lawson, A, additional, Lee, C, additional, Leung-Tack, M, additional, Li Saw Hee, J, additional, Mostafa, O, additional, Nair, D, additional, Pattani, N, additional, Plumbley-Jones, J, additional, Pufal, K, additional, Ramesh, P, additional, Sanghera, J, additional, Saram, S, additional, Scadding, S, additional, See, S, additional, Stringer, H, additional, Torrance, A, additional, Vardon, H, additional, Wyn-Griffiths, F, additional, Brew, A, additional, Kaur, G, additional, Soni, D, additional, Tickle, A, additional, Akbar, Z, additional, Appleyard, T, additional, Figg, K, additional, Jayawardena, P, additional, Johnson, A, additional, Kamran Siddiqui, Z, additional, Lacy-Colson, J, additional, Oatham, R, additional, Rowlands, B, additional, Sludden, E, additional, Turnbull, C, additional, Allin, D, additional, Ansar, Z, additional, Azeez, Z, additional, Dale, VH, additional, Garg, J, additional, Horner, A, additional, Jones, S, additional, Knight, S, additional, McGregor, C, additional, McKenna, J, additional, McLelland, T, additional, Packham-Smith, A, additional, Rowsell, K, additional, Spector-Hill, I, additional, Adeniken, E, additional, Baker, J, additional, Bartlett, M, additional, Chikomba, L, additional, Connell, B, additional, Deekonda, P, additional, Dhar, M, additional, Elmansouri, A, additional, Gamage, K, additional, Goodhew, R, additional, Hanna, P, additional, Knight, J, additional, Luca, A, additional, Maasoumi, N, additional, Mahamoud, F, additional, Manji, S, additional, Marwaha, PK, additional, Mason, F, additional, Oluboyede, A, additional, Pigott, L, additional, Razaq, AM, additional, Richardson, M, additional, Saddaoui, I, additional, Wijeyendram, P, additional, Yau, S, additional, Atkins, W, additional, Liang, K, additional, Miles, N, additional, Praveen, B, additional, Ashai, S, additional, Braganza, J, additional, Common, J, additional, Cundy, A, additional, Davies, R, additional, Guthrie, J, additional, Handa, I, additional, Iqbal, M, additional, Ismail, R, additional, Jones, C, additional, Jones, I, additional, Lee, KS, additional, Levene, A, additional, Okocha, M, additional, Olivier, J, additional, Smith, A, additional, Subramaniam, E, additional, Tandle, S, additional, Wang, A, additional, Watson, A, additional, Wilson, C, additional, Chan, XHF, additional, Khoo, E, additional, Montgomery, C, additional, Norris, M, additional, Pugalenthi, PP, additional, Common, T, additional, Cook, E, additional, Mistry, H, additional, Shinmar, HS, additional, Agarwal, G, additional, Bandyopadhyay, S, additional, Brazier, B, additional, Carroll, L, additional, Goede, A, additional, Harbourne, A, additional, Lakhani, A, additional, Lami, M, additional, Larwood, J, additional, Martin, J, additional, Merchant, J, additional, Pattenden, S, additional, Pradhan, A, additional, Raafat, N, additional, Rothwell, E, additional, Shammoon, Y, additional, Sudarshan, R, additional, Vickers, E, additional, Wingfield, L, additional, Ashworth, I, additional, Azizi, S, additional, Bhate, R, additional, Chowdhury, T, additional, Christou, A, additional, Davies, L, additional, Dwaraknath, M, additional, Farah, Y, additional, Garner, J, additional, Gureviciute, E, additional, Hart, E, additional, Jain, A, additional, Javid, S, additional, Kankam, HK, additional, Kaur Toor, P, additional, Kaz, R, additional, Kermali, M, additional, Khan, I, additional, Mattson, A, additional, McManus, A, additional, Murphy, M, additional, Nair, K, additional, Ngemoh, D, additional, Norton, E, additional, Olabiran, A, additional, Parry, L, additional, Payne, T, additional, Pillai, K, additional, Price, S, additional, Punjabi, K, additional, Raghunathan, A, additional, Ramwell, A, additional, Raza, M, additional, Ritehnia, J, additional, Simpson, G, additional, Smith, W, additional, Sodeinde, S, additional, Studd, L, additional, Subramaniam, M, additional, Thomas, J, additional, Towey, S, additional, Tsang, E, additional, Tuteja, D, additional, Vasani, J, additional, Vio, M, additional, Badran, A, additional, Adams, J, additional, Anthony Wilkinson, J, additional, Asvandi, S, additional, Austin, T, additional, Bald, A, additional, Bix, E, additional, Carrick, M, additional, Chander, B, additional, Chowdhury, S, additional, Cooper Drake, B, additional, Crosbie, S, additional, D Portela, S, additional, Francis, D, additional, Gallagher, C, additional, Gillespie, R, additional, Gravett, H, additional, Gupta, P, additional, Ilyas, C, additional, James, G, additional, Johny, J, additional, Jones, A, additional, Kinder, F, additional, MacLeod, C, additional, Macrow, C, additional, Maqsood-Shah, A, additional, Mather, J, additional, McCann, L, additional, McMahon, R, additional, Mitham, E, additional, Mohamed, M, additional, Munton, E, additional, Nightingale, K, additional, O'Neill, K, additional, Onyemuchara, I, additional, Senior, R, additional, Shanahan, A, additional, Sherlock, J, additional, Spyridoulias, A, additional, Stavrou, C, additional, Stokes, D, additional, Tamang, R, additional, Taylor, E, additional, Trafford, C, additional, Uden, C, additional, Waddington, C, additional, Yassin, D, additional, Zaman, M, additional, Bangi, S, additional, Cheng, T, additional, Chew, D, additional, Hussain, N, additional, Imani-Masouleh, S, additional, Mahasivam, G, additional, McKnight, G, additional, Ng, HL, additional, Ota, HC, additional, Pasha, T, additional, Ravindran, W, additional, Shah, K, additional, Vishnu K, S, additional, Zaman, S, additional, Carr, W, additional, Cope, S, additional, Eagles, EJ, additional, Howarth-Maddison, M, additional, Li, CY, additional, Reed, J, additional, Ridge, A, additional, Stubbs, T, additional, Teasdaled, D, additional, Umar, R, additional, Worthington, J, additional, Dhebri, A, additional, Kalenderov, R, additional, Alattas, A, additional, Arain, Z, additional, Bhudia, R, additional, Chia, D, additional, Daniel, S, additional, Dar, T, additional, Garland, H, additional, Girish, M, additional, Hampson, A, additional, Kyriacou, H, additional, Lehovsky, K, additional, Mullins, W, additional, Omorphos, N, additional, Vasdev, N, additional, Venkatesh, A, additional, Waldock, W, additional, Bhandari, A, additional, Brown, G, additional, Choa, G, additional, Eichenauer, CE, additional, Ezennia, K, additional, Kidwai, Z, additional, Lloyd-Thomas, A, additional, Macaskill Stewart, A, additional, Massardi, C, additional, Sinclair, E, additional, Skajaa, N, additional, Smith, M, additional, Tan, I, additional, Afsheen, N, additional, Anuar, A, additional, Azam, Z, additional, Bhatia, P, additional, Davies-kelly, N, additional, Dickinson, S, additional, Elkawafi, M, additional, Ganapathy, M, additional, Gupta, S, additional, Khoury, EG, additional, Licudi, D, additional, Mehta, V, additional, Neequaye, S, additional, Nita, G, additional, Tay, VL, additional, Zhao, S, additional, Botsa, E, additional, Cuthbert, H, additional, Elliott, J, additional, Furlepa, M, additional, Lehmann, J, additional, Mangtani, A, additional, Narayan, A, additional, Nazarian, S, additional, Parmar, C, additional, Shah, D, additional, Shaw, C, additional, Zhao, Z, additional, Beck, C, additional, Caldwell, S, additional, Clements, JM, additional, French, B, additional, Kenny, R, additional, Kirk, S, additional, Lindsay, J, additional, McClung, A, additional, McLaughlin, N, additional, Watson, S, additional, Whiteside, E, additional, Alyacoubi, S, additional, Arumugam, V, additional, Beg, R, additional, Dawas, K, additional, Garg, S, additional, Lloyd, ER, additional, Mahfouz, Y, additional, Manobharath, N, additional, Moonesinghe, R, additional, Morka, N, additional, Patel, K, additional, Prashar, J, additional, Yip, S, additional, Adeeko, ES, additional, Ajekigbe, F, additional, Bhat, A, additional, Evans, C, additional, Farrugia, A, additional, Gurung, C, additional, Long, T, additional, Malik, B, additional, Manirajan, S, additional, Newport, D, additional, Rayer, J, additional, Ridha, A, additional, Ross, E, additional, Saran, T, additional, Sinker, A, additional, Waruingi, D, additional, Allen, R, additional, Al Sadek, Y, additional, Alves do Canto Brum, H, additional, Asharaf, H, additional, Ashman, M, additional, Balakumar, V, additional, Barrington, J, additional, Baskaran, R, additional, Berry, A, additional, Bhachoo, H, additional, Bilal, A, additional, Boaden, L, additional, Chia, WL, additional, Covell, G, additional, Crook, D, additional, Dadnam, F, additional, Davis, L, additional, De Berker, H, additional, Doyle, C, additional, Fox, C, additional, Gruffydd-Davies, M, additional, Hafouda, Y, additional, Hill, A, additional, Hubbard, E, additional, Hunter, A, additional, Inpadhas, V, additional, Jamshaid, M, additional, Jandu, G, additional, Jeyanthi, M, additional, Jones, T, additional, Kantor, C, additional, Kwak, SY, additional, Malik, N, additional, Matt, R, additional, McNulty, P, additional, Miles, C, additional, Mohomed, A, additional, Myat, P, additional, Niharika, J, additional, Nixon, A, additional, O'Reilly, D, additional, Parmar, K, additional, Pengelly, S, additional, Price, L, additional, Ramsden, M, additional, Turnor, R, additional, Wales, E, additional, Waring, H, additional, Wu, M, additional, Yang, T, additional, Ye, TTS, additional, Zander, A, additional, Zeicu, C, additional, Bellam, S, additional, Francombe, J, additional, Kawamoto, N, additional, Rahman, MR, additional, Sathyanarayana, A, additional, Tang, HT, additional, Cheung, J, additional, Hollingshead, J, additional, Page, V, additional, Sugarman, J, additional, Wong, E, additional, Chiong, J, additional, Fung, E, additional, Kan, SY, additional, Kiang, J, additional, Kok, J, additional, Krahelski, O, additional, Liew, MY, additional, Lyell, B, additional, Sharif, Z, additional, Speake, D, additional, Alim, L, additional, Amakye, NY, additional, Chandrasekaran, J, additional, Chandratreya, N, additional, Drake, J, additional, Owoso, T, additional, Thu, YM, additional, Abou El Ela Bourquin, B, additional, Alberts, J, additional, Chapman, D, additional, Rehnnuma, N, additional, Ainsworth, K, additional, Carpenter, H, additional, Emmanuel, T, additional, Fisher, T, additional, Gabrel, M, additional, Guan, Z, additional, Hollows, S, additional, Hotouras, A, additional, Ip Fung Chun, N, additional, Jaffer, S, additional, Kallikas, G, additional, Kennedy, N, additional, Lewinsohn, B, additional, Liu, FY, additional, Mohammed, S, additional, Rutherfurd, A, additional, Situ, T, additional, Stammer, A, additional, Taylor, F, additional, Thin, N, additional, Urgesi, E, additional, Zhang, N, additional, Ahmad, MA, additional, Bishop, A, additional, Bowes, A, additional, Dixit, A, additional, Glasson, R, additional, Hatta, S, additional, Hatt, K, additional, Larcombe, S, additional, Preece, J, additional, Riordan, E, additional, Fegredo, D, additional, Haq, MZ, additional, Li, C, additional, McCann, G, additional, Stewart, D, additional, Baraza, W, additional, Bhullar, D, additional, Burt, G, additional, Coyle, J, additional, Deans, J, additional, Devine, A, additional, Hird, R, additional, Ikotun, O, additional, Manchip, G, additional, Ross, C, additional, Storey, L, additional, Tan, WWL, additional, Tse, C, additional, Warner, C, additional, Whitehead, M, additional, Wu, F, additional, Court, EL, additional, Crisp, E, additional, Huttman, M, additional, Mayes, F, additional, Robertson, H, additional, Rosen, H, additional, Sandberg, C, additional, Smith, H, additional, Al Bakry, M, additional, Ashwell, W, additional, Bajaj, S, additional, Bandyopadhyay, D, additional, Browlee, O, additional, Burway, S, additional, Chand, CP, additional, Elsayeh, K, additional, Elsharkawi, A, additional, Evans, E, additional, Ferrin, S, additional, Fort-Schaale, A, additional, Iacob, M, additional, I, K, additional, Impelliziere Licastro, G, additional, Mankoo, AS, additional, Olaniyan, T, additional, Otun, J, additional, Pereira, R, additional, Reddy, R, additional, Saeed, D, additional, Simmonds, O, additional, Singhal, G, additional, Tron, K, additional, Wickstone, C, additional, Williams, R, additional, Bradshaw, E, additional, De Kock Jewell, V, additional, Houlden, C, additional, Knight, C, additional, Metezai, H, additional, Mirza-Davies, A, additional, Seymour, Z, additional, Spink, D, additional, and Wischhusen, S, additional

Published
2022
Full Text
View/download PDF

15. A Multicenter, International Collaborative Study for American Joint Committee on Cancer Staging of Retinoblastoma

Author

Andrey A. Yarovoy, Jason C. S. Yam, Tero Kivelä, Brenda L. Gallie, Jonathan W. Kim, Ekaterina Semenova, Guillermo Chantada, Genoveva Correa-Llano, Adriana Fandiño, Matthew W. Wilson, Suganeswari Ganesan, Ashwin Mallipatna, Jaume Català, Sonia Moorthy, Elisa Carreras, Olga V Yugay, Ankit Singh Tomar, Junyang Zhao, Marco A. Ramirez-Ortiz, Tatiana L Ushakova, Michala Burges, Vikas Khetan, Vera Adobea Essuman, Chengyue Zhang, Winnie W. Y. Lau, V.G. Polyakov, Yacoub A. Yousef, Paula Schaiquevich, Kalle Nummi, Carol P. S. Lam, Phillipa Sharwood, Rachel C. Brenna, Paul T. Finger, Elena Kotova, Quah Boon Long, Vera Yarovaya, Lorna Renner, and Elizabeth Esparza-Aguiar

Subjects
0303 health sciences, Chemotherapy, medicine.medical_specialty, genetic structures, Retinoblastoma, business.industry, medicine.medical_treatment, Enucleation, Cancer, medicine.disease, Intraocular Retinoblastoma, eye diseases, Treatment failure, 3. Good health, Surgery, 03 medical and health sciences, Ophthalmology, 0302 clinical medicine, Treatment success, 030221 ophthalmology & optometry, medicine, sense organs, business, 030304 developmental biology, Cancer staging
Abstract

Purpose To evaluate the ability of the American Joint Committee on Cancer (AJCC) 8th edition to predict local tumor control and globe salvage for children with retinoblastoma (RB). Design International, multicenter, registry-based retrospective case series. Participants A total of 2854 eyes of 2097 patients from 18 ophthalmic oncology centers from 13 countries over 6 continents. Methods International, multicenter, registry-based data were pooled from patients enrolled between January 2001 and December 2013. All RB eyes with adequate records to allow tumor staging by the AJCC 8th edition criteria and follow-up to ascertain treatment outcomes were included. Main Outcome Measures Globe-salvage rates were estimated by AJCC clinical (cTNMH) categories and tumor laterality. Local treatment failure was defined as use of enucleation or external beam radiation therapy (EBRT), with or without plaque brachytherapy or intra-arterial chemotherapy (IAC). Results Unilateral RB occurred in 1340 eyes (47%). Among the 2854 eyes, tumor categories were cT1 to cT4 in 696 eyes (24%), 1334 eyes (47%), 802 eyes (28%), and 22 eyes (1%), respectively. Of these, 1275 eyes (45%) were salvaged, and 1179 eyes (41%) and 400 eyes (14%) underwent primary and secondary enucleation, respectively. The 2- and 5-year Kaplan–Meier cumulative globe-salvage rates without the use of EBRT by cTNMH categories were 97% and 96% for category cT1a tumors, 94% and 88% for cT1b tumors, 68% and 60% for cT2a tumors, 66% and 57% for cT2b tumors, and 32% and 25% for cT3 tumors, respectively. Risk of local treatment failure increased with increasing cT category (P Conclusions Multicenter, international, internet-based data sharing validated the 8th edition AJCC RB staging to predict globe-salvage in a large, heterogeneous, real-world patient population with RB.

Published
2020

16. A Multicenter, International Collaborative Study for American Joint Committee on Cancer Staging of Retinoblastoma

Author

Kalle Nummi, Carol P. S. Lam, Phillipa Sharwood, Tero Kivelä, Brenda L. Gallie, Adriana Fandiño, Quah Boon Long, Vera Yarovaya, Guillermo Chantada, Sonia Moorthy, Jason C. S. Yam, Tatiana L Ushakova, Jaume Català, Matthew W. Wilson, Marco A. Ramirez-Ortiz, Winnie W. Y. Lau, Lorna Renner, Junyang Zhao, Ashwin Mallipatna, Chengyue Zhang, Ankit Singh Tomar, Vikas Khetan, V.G. Polyakov, Vera Adobea Essuman, Elizabeth Esparza-Aguiar, Suganeswari Ganesan, Jonathan W. Kim, Olga V Yugay, Genoveva Correa-Llano, Andrey A. Yarovoy, Paula Schaiquevich, Paul T. Finger, Elena Kotova, and Yacoub A. Yousef

Subjects
0303 health sciences, medicine.medical_specialty, Trilateral retinoblastoma, business.industry, Mortality rate, Enucleation, Cancer, medicine.disease, Confidence interval, 3. Good health, Metastasis, 03 medical and health sciences, Ophthalmology, 0302 clinical medicine, Internal medicine, 030221 ophthalmology & optometry, Medicine, business, Pathological, 030304 developmental biology, Cancer staging
Abstract

Purpose To evaluate the ability of the 8th edition of the American Joint Committee on Cancer (AJCC) Cancer Staging Manual to estimate metastatic and mortality rates for children with retinoblastoma (RB). Design International, multicenter, registry-based retrospective case series. Participants A total of 2190 patients from 18 ophthalmic oncology centers from 13 countries over 6 continents. Methods Patient-specific data fields for RB were designed and selected by subcommittee. All patients with RB with adequate records to allow tumor staging by the AJCC criteria and follow-up for metastatic disease were studied. Main Outcome Measures Metastasis-related 5- and 10-year survival data after initial tumor staging were estimated with the Kaplan–Meier method depending on AJCC clinical (cTNM) and pathological (pTNM) tumor, node, metastasis category and age, tumor laterality, and presence of heritable trait. Results Of 2190 patients, the records of 2085 patients (95.2%) with 2905 eyes were complete. The median age at diagnosis was 17.0 months. A total of 1260 patients (65.4%) had unilateral RB. Among the 2085 patients, tumor categories were cT1a in 55 (2.6%), cT1b in 168 (8.1%), cT2a in 197 (9.4%), cT2b in 812 (38.9%), cT3 in 835 (40.0%), and cT4 in 18 (0.9%). Of these, 1397 eyes in 1353 patients (48.1%) were treated with enucleation. A total of 109 patients (5.2%) developed metastases and died. The median time (n = 92) from diagnosis to metastasis was 9.50 months. The 5-year Kaplan–Meier cumulative survival estimates by clinical tumor categories were 100% for category cT1a, 98% (95% confidence interval [CI], 97–99) for cT1b and cT2a, 96% (95% CI, 95–97) for cT2b, 89% (95% CI, 88–90) for cT3 tumors, and 45% (95% CI, 31–59) for cT4 tumors. Risk of metastasis increased with increasing cT (and pT) category (P Conclusions Multicenter, international, internet-based data sharing facilitated analysis of the 8th edition AJCC RB Staging System for metastasis-related mortality and offered a proof of concept yielding quantitative, predictive estimates per category in a large, real-life, heterogeneous patient population with RB.

Published
2020

17. Screening for Pineal Trilateral Retinoblastoma Revisited

Author

Furqan Shaikh, Wijnanda A. Kors, Brenda L. Gallie, Annette C. Moll, Tero Kivelä, Robin W. Jansen, Helen Dimaras, Pim de Graaf, Sameh E. Soliman, Marcus C. de Jong, and Jonas A. Castelijns

Subjects
Pineoblastoma, endocrine system, medicine.medical_specialty, Pediatrics, Trilateral retinoblastoma, Retinoblastoma, business.industry, medicine.disease, Intraocular Retinoblastoma, Asymptomatic, 3. Good health, 03 medical and health sciences, Ophthalmology, 0302 clinical medicine, Interquartile range, 030220 oncology & carcinogenesis, Epidemiology, 030221 ophthalmology & optometry, medicine, Pinealoblastoma, medicine.symptom, 10. No inequality, business
Abstract

Topic To determine the age up to which children are at risk of trilateral retinoblastoma (TRb) developing, whether its onset is linked to the age at which intraocular retinoblastomas develop, and the lead time from a detectable pineal TRb to symptoms. Clinical relevance Approximately 45% of patients with retinoblastoma—those with a germline RB1 pathogenic variant—are at risk of pineal TRb developing. Early detection and treatment are essential for survival. Current evidence is unclear regarding the usefulness of screening for pineal TRb and, if useful, the age up to which screening should be continued. Methods We conducted a study according to the Meta-analysis of Observational Studies in Epidemiology guidelines for reporting meta-analyses of observational studies. We searched PubMed and Embase between January 1, 1966, and February 27, 2019, for published literature. We considered articles reporting patients with TRb with survival and follow-up data. Inclusion of articles was performed separately and independently by 2 authors, and 2 authors also independently extracted the relevant data. They resolved discrepancies by consensus. Results One hundred thirty-eight patients with pineal TRb were included. Of 22 asymptomatic patients, 21 (95%) were diagnosed before the age of 40 months (median, 16 months; interquartile range, 9–29 months). Age at diagnosis of pineal TRb in patients diagnosed with retinoblastoma at 6 months or younger versus older than 6 months were comparable (P = 0.44), suggesting independence between the ages at diagnosis of intraocular retinoblastoma and pineal TRb. The laterality of intraocular retinoblastoma and its treatment were not associated with the age at which pineal TRb was diagnosed. The lead time from asymptomatic to symptomatic pineal TRb was approximately 1 year. By performing a screening magnetic resonance imaging scan every 6 months after the diagnosis of heritable retinoblastoma (median age, 6 months) until 36 months of age, at least 311 and 776 scans would be required to detect 1 case of asymptomatic pineal TRb and to save a single life, respectively. Conclusions Patients with retinoblastoma are at risk of pineal TRb developing for a shorter period than previously assumed, and the age at diagnosis of pineal TRb is independent of the age at diagnosis of retinoblastoma. The GRADE (Grading of Recommendations Assessment, Development and Evaluation) level of evidence for these conclusions remains low.

Published
2020

18. Secondary Prevention of Retinoblastoma Revisited

Author

Brenda L. Gallie, Sameh E. Soliman, Cynthia VandenHoven, and Leslie D. Mackeen

Subjects
medicine.medical_specialty, medicine.medical_treatment, Posterior pole, Scars, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, medicine, 030304 developmental biology, Secondary prevention, 0303 health sciences, business.industry, Retinoblastoma, Retinal, Retrospective cohort study, medicine.disease, eye diseases, Ophthalmology, medicine.anatomical_structure, chemistry, 030221 ophthalmology & optometry, Radiology, medicine.symptom, business, Laser coagulation, Optic disc
Abstract

Purpose Invisible retinoblastoma tumors are now detected with screening for retinal tumors in at-risk neonates (those inheriting RB1 pathogenic alleles from affected parents) using handheld OCT. Laser photocoagulation is challenging, requiring exact localization of a tumor invisible to indirect ophthalmoscopy and standard imaging. We describe OCT-guided localization and photocoagulation of these invisible tumors with 1-year follow-up. Design Retrospective, noncomparative, single-institutional, observational case series. Participants Children with any clinically invisible retinoblastoma tumor that was detected on OCT posterior pole screening. Methods OCT revealed round homogeneous invisible tumors within the inner nuclear layer. Software calipers placed beside anatomic retinal landmarks (branched/curved vessels, fovea, or optic disc) mapped the tumor location and extent. A single laser (532 nm) burn flagged the location, and OCT evaluated the tumor–laser burn relationship; laser treatment was then continued in the correct location. Post-laser OCT ensured complete treatment. Main Outcome Measures Accuracy (frequency of geographic miss and skip areas), effectiveness (recurrence rate), and burden (scar size and characteristics at final follow-up) of laser treatment. Results Eleven new invisible posterior pole tumors in 7 eyes of 5 children were treated by this technique. Localization and tumor–laser burn relationships were accurate in 11 of 11 tumors (100%, 95% confidence interval [CI], 49.9–100), and all showed swelling and hyper-reflectiveness of the tumor in post-laser OCT. Two photocoagulation sessions (2 weeks apart) were sufficient to successfully manage 9 of 11 tumors (82%, 95% CI, 37.4–100) with resulting permanent flat scars. One tumor (9%, 95% CI, 0.2–50.6) developed OCT-detected subclinical recurrences within 3 months, treated by 1 laser session. No treatment scar showed gliosis, foveal involvement, or retinal traction at 1-year follow-up. Scar expansion occurred in 1 tumor (9%, 95% CI, 0.2–50.6), and all scars (100%, 95% CI, 49.9–100) showed pigmentary changes. Conclusions The OCT-guided localization and photocoagulation technique is valuable in achieving precision results in managing invisible new retinoblastoma tumors. This technique shows a potential to improve outcomes of secondary prevention screening for retinoblastoma.

Published
2020

22. Global Retinoblastoma Treatment Outcomes

Author

Tomar, Ankit Singh, primary, Finger, Paul T., additional, Gallie, Brenda, additional, Kivelä, Tero T., additional, Mallipatna, Ashwin, additional, Zhang, Chengyue, additional, Zhao, Junyang, additional, Wilson, Matthew W., additional, Brenna, Rachel C., additional, Burges, Michala, additional, Kim, Jonathan, additional, Khetan, Vikas, additional, Ganesan, Suganeswari, additional, Yarovoy, Andrey, additional, Yarovaya, Vera, additional, Kotova, Elena, additional, Yousef, Yacoub A., additional, Nummi, Kalle, additional, Ushakova, Tatiana L., additional, Yugay, Olga V., additional, Polyakov, Vladimir G., additional, Ramirez-Ortiz, Marco A., additional, Esparza-Aguiar, Elizabeth, additional, Chantada, Guillermo, additional, Schaiquevich, Paula, additional, Fandino, Adriana, additional, Yam, Jason C., additional, Lau, Winnie W., additional, Lam, Carol P., additional, Sharwood, Phillipa, additional, Moorthy, Sonia, additional, Long, Quah Boon, additional, Essuman, Vera Adobea, additional, Renner, Lorna A., additional, Semenova, Ekaterina, additional, Català, Jaume, additional, Correa-Llano, Genoveva, additional, and Carreras, Elisa, additional

Published
2021
Full Text
View/download PDF

24. Screening Children at Risk for Retinoblastoma

Author

Patricia Chévez-Barrios, Dan S. Gombos, Carol L. Shields, Brian P. Marr, Jonathan W. Kim, Alison H. Skalet, Brenda L. Gallie, and Sharon E. Plon

Subjects
Gynecology, medicine.medical_specialty, medicine.diagnostic_test, business.industry, Retinoblastoma, Genetic counseling, medicine.disease, eye diseases, 03 medical and health sciences, Ophthalmology, 0302 clinical medicine, 030220 oncology & carcinogenesis, Family medicine, 030221 ophthalmology & optometry, Medicine, Pediatric ophthalmology, Population Risk, Family history, business, Risk assessment, Mass screening, Genetic testing
Abstract

Purpose To provide a set of surveillance guidelines for children at risk for development of retinoblastoma. Design Consensus panel. Participants Expert panel of ophthalmic oncologists, pathologists, and geneticists. Methods A group of members of the American Association of Ophthalmic Oncologists and Pathologists (AAOOP) with support of the American Association for Pediatric Ophthalmology and Strabismus and the American Academy of Pediatrics (AAP) was convened. The panel included representative ophthalmic oncologists, pathologists, and geneticists from retinoblastoma referral centers located in various geographic regions who met and discussed screening approaches for retinoblastoma. A patient "at risk" was defined as a person with a family history of retinoblastoma in a parent, sibling, or first- or second-degree relative. Main Outcome Measures Screening recommendations for children at risk for retinoblastoma. Results Consensus statement from the panel: (1) Dedicated ophthalmic screening is recommended for all children at risk for retinoblastoma above the population risk. (2) Frequency of examinations is adjusted on the basis of expected risk for RB1 mutation. (3) Genetic counseling and testing clarify the risk for retinoblastoma in children with a family history of the disease. (4) Examination schedules are stratified on the basis of high-, intermediate-, and low-risk children. (5) Children at high risk for retinoblastoma require more frequent screening, which may preferentially be examinations under anesthesia. Conclusions Risk stratification including genetic testing and counseling serves as the basis for screening of children at elevated risk for development of retinoblastoma.

Published
2018

25. A Multicenter, International Collaborative Study for American Joint Committee on Cancer Staging of Retinoblastoma

Author

Tomar, Ankit Singh, primary, Finger, Paul T., additional, Gallie, Brenda, additional, Mallipatna, Ashwin, additional, Kivelä, Tero T., additional, Zhang, Chengyue, additional, Zhao, Junyang, additional, Wilson, Matthew W., additional, Kim, Jonathan, additional, Khetan, Vikas, additional, Ganesan, Suganeswari, additional, Yarovoy, Andrey, additional, Yarovaya, Vera, additional, Kotova, Elena, additional, Yousef, Yacoub A., additional, Nummi, Kalle, additional, Ushakova, Tatiana L., additional, Yugay, Olga V., additional, Polyakov, Vladimir G., additional, Ramirez-Ortiz, Marco A., additional, Esparza-Aguiar, Elizabeth, additional, Chantada, Guillermo, additional, Schaiquevich, Paula, additional, Fandino, Adriana, additional, Yam, Jason C., additional, Lau, Winnie W., additional, Lam, Carol P., additional, Sharwood, Phillipa, additional, Moorthy, Sonia, additional, Long, Quah Boon, additional, Essuman, Vera Adobea, additional, Renner, Lorna A., additional, Català, Jaume, additional, and Correa-Llano, Genoveva, additional

Published
2020
Full Text
View/download PDF

26. Pediatric cataract surgery following treatment for retinoblastoma

Author

Asim Ali, Kamiar Mireskandari, Stephanie N. Kletke, Brenda L. Gallie, and Ashwin Mallipatna

Subjects
Ophthalmology, medicine.medical_specialty, business.industry, Retinoblastoma, Pediatrics, Perinatology and Child Health, medicine, Pediatric cataract, business, medicine.disease, Surgery
Published
2021

27. Primary laser therapy as monotherapy for discrete retinoblastoma

Author

Brenda L. Gallie, Zhao Xun Feng, and Sameh E. Soliman

Subjects
Chemotherapy, medicine.medical_specialty, business.industry, Retinoblastoma, medicine.medical_treatment, Brachytherapy, Less invasive, Vitreous seeding, medicine.disease, Ophthalmology, Laser therapy, Pediatrics, Perinatology and Child Health, Medicine, Radiology, business
Abstract

Background/aim Laser photocoagulation is less invasive than chemotherapy (systemic, intra-arterial or periocular) and brachytherapy. We studied the safety and efficacy of laser as primary monotherapy for discrete retinoblastoma with well-defined borders and attached retina. Methods A single-institution retrospective non-comparative review (2004–2018) of discrete retinoblastoma tumours managed with primary laser (532 or 810 nm wavelength, 0.5–1 s duration and power titrated until desired tumour whitening). Efficacy was evaluated by tumour long-term stability avoiding non-laser therapies. Safety was evaluated by frequency of laser-related complications and uncontrollable tumour progression. Results Eligible were 112 tumours in 55 eyes of 44 patients. Laser monotherapy (median 2 sessions) achieved initial remission in 95/112 (85%) tumour. Initial encircling only laser photocoagulation was associated with tumour progression (9/11, one tumour had vitreous seeding) compared with direct or combined photocoagulation techniques (0/94 and 0/7 tumours, respectively, p 3 DD achieved long-term stability with laser monotherapy (p Conclusions Discrete retinoblastoma ≤3 DD can be effectively and safely managed with laser monotherapy, sparing a significant proportion of patients/eyes from more invasive therapies.

Published
2021

29. Screening for Pineal Trilateral Retinoblastoma Revisited

Author

de Jong, Marcus C., primary, Kors, Wijnanda A., additional, Moll, Annette C., additional, de Graaf, Pim, additional, Castelijns, Jonas A., additional, Jansen, Robin W., additional, Gallie, Brenda, additional, Soliman, Sameh E., additional, Shaikh, Furqan, additional, Dimaras, Helen, additional, and Kivelä, Tero T., additional

Published
2020
Full Text
View/download PDF

31. Optical Coherence Tomography–Guided Decisions in Retinoblastoma Management

Author

Brenda L. Gallie, Sameh E. Soliman, Leslie D. Mackeen, Cynthia VandenHoven, and Elise Héon

Subjects
Image-Guided Biopsy, Male, 0301 basic medicine, medicine.medical_specialty, Visual acuity, genetic structures, Retinal Neoplasms, Ubiquitin-Protein Ligases, DNA Mutational Analysis, Decision Making, Posterior pole, Visual Acuity, Retina, 03 medical and health sciences, 0302 clinical medicine, Optical coherence tomography, medicine, Humans, Family history, Child, Neoplasm Staging, Retrospective Studies, Cancer staging, medicine.diagnostic_test, Retinoblastoma, business.industry, Disease Management, Retrospective cohort study, DNA, Neoplasm, medicine.disease, eye diseases, Surgery, Retinoblastoma Binding Proteins, Ophthalmology, 030104 developmental biology, Child, Preschool, 030221 ophthalmology & optometry, Female, sense organs, Radiology, medicine.symptom, business, Unilateral Retinoblastoma, Tomography, Optical Coherence
Abstract

Purpose Assess the role of handheld optical coherence tomography (OCT) in guiding management decisions during diagnosis, treatment, and follow-up of eyes affected by retinoblastoma. Design Retrospective, noncomparative, single-institution case series. Participants All children newly diagnosed with retinoblastoma from January 2011 to December 2015 who had an OCT session during their active treatment at The Hospital for Sick Children (SickKids) in Toronto, Canada. The OCT sessions for fellow eyes of unilateral retinoblastoma without any suspicious lesion and those performed more than 6 months after the last treatment were excluded. Methods Data collected included age at presentation, sex, family history, RB1 mutation status, 8th edition TNMH cancer staging and International Intraocular Retinoblastoma Classification (IIRC), and number of OCT sessions per eye. Details of each session were scored for indication-related details (informative or not) and assessed for guidance (directive or not), diagnosis (staging changed, new tumors found or excluded), treatment (modified, stopped, or modality shifted), or follow-up modified. Main Outcome Measures Frequency of OCT-guided management decisions, stratified by indication and type of guidance (confirmatory vs. influential). Results Sixty-three eyes of 44 children had 339 OCT sessions over the course of clinical management (median number of OCT scans per eye, 5; range, 1–15). The age at presentation and presence of a heritable RB1 mutation significantly correlated with an increased number of OCT sessions. Indications included evaluation of post-treatment scar (55%) or fovea (16%), and posterior pole scanning for new tumors (11%). Of all sessions, 92% (312/339) were informative; 19 of 27 noninformative sessions had large, elevated lesions; of these, 14 of 19 were T2a or T2b (IIRC group C or D) eyes. In 94% (293/312) of the informative sessions, OCT directed treatment decisions (58%), diagnosis (16%), and follow-up (26%). Optical coherence tomography influenced and changed management from pre-OCT clinical plans in 15% of all OCT sessions and 17% of directive sessions. Conclusions Optical coherence tomography improves the accuracy of clinical evaluation in retinoblastoma management.

Published
2017

32. Prenatal versus Postnatal Screening for Familial Retinoblastoma

Author

Vikas Khetan, Sameh E. Soliman, Jane Gardiner, Helen Dimaras, Elise Héon, Brenda L. Gallie, and Helen S. L. Chan

Subjects
Male, Postnatal Care, Pediatrics, medicine.medical_specialty, Term Birth, Retinal Neoplasms, Ubiquitin-Protein Ligases, Visual Acuity, Gestational Age, Prenatal diagnosis, Eye Enucleation, 03 medical and health sciences, Neonatal Screening, 0302 clinical medicine, Pregnancy, Prenatal Diagnosis, Antineoplastic Combined Chemotherapy Protocols, medicine, Humans, Retrospective Studies, Salvage Therapy, medicine.diagnostic_test, Retinoblastoma, business.industry, Infant, Newborn, Gestational age, Retrospective cohort study, medicine.disease, eye diseases, Retinoblastoma Binding Proteins, Ophthalmology, Early Diagnosis, Treatment Outcome, 030220 oncology & carcinogenesis, Cohort, Amniocentesis, 030221 ophthalmology & optometry, Female, business
Abstract

Purpose To compare overall outcomes of conventional postnatal screening of familial retinoblastoma and prenatal RB1 mutation identification followed by planned early-term delivery. Design Retrospective, observational study. Participants Twenty children with familial retinoblastoma born between 1996 and 2014 and examined within 1 week of birth. Methods Cohort 1 included spontaneously delivered neonates examined within 1 week of birth and confirmed postnatal to carry their family's RB1 mutant allele. Cohort 2 included infants identified by amniocentesis to carry their family's RB1 mutant allele, and therefore scheduled for early-term delivery (36–38 weeks' gestation). Treatment for retinoblastoma was performed at the Hospital for Sick Children, Toronto, Canada. Main Outcome Measures Age at first tumor in each eye, eye stage, treatments given, ocular salvage, treatment success (defined as avoidance of enucleation, external-beam irradiation, or both), visual outcome, number of anesthetics, pregnancy or delivery complications, and estimated treatment burden. Results Vision-threatening tumors were present at birth in 4 of 8 infants in cohort 1 and in 3 of 12 infants in cohort 2. Eventually, all infants demonstrated tumors in both eyes. At the first treatment, 1 of 8 infants in cohort 1 had eyes in stage cT1a/cT1a or cT1a/cT0 (smallest and least vision-threatening tumors), compared with 8 of 12 infants in cohort 2 ( P = 0.02). Null RB1 germline alleles induced earlier tumors than low-penetrance alleles ( P = 0.03). Treatment success was achieved in 3 of 8 children in cohort 1 compared with 11 of 12 children in cohort 2 ( P = 0.002). Acceptable vision (better than 0.2 decimal) was achieved for 8 of 16 eyes in cohort 1 compared with 21 of 24 eyes in cohort 2 ( P = 0.014). Useful vision (better than 0.1, legal blindness) was achieved for 8 of 9 children in cohort 1 compared with 12 of 12 children in cohort 2. There were no complications related to early-term delivery. Median follow-up was 5.6 years, cohort 1 and 5.8 years, cohort 2. Conclusions When a parent had retinoblastoma, prenatal molecular diagnosis with early-term delivery increased the likelihood of infants born with no detectable tumors, better vision outcomes, and less invasive therapy. Prenatal molecular diagnosis facilitates anticipatory planning for both the child and family.

Published
2016

33. Pars Plana Vitrectomy and Endoresection of Refractory Intraocular Retinoblastoma

Author

Songyi Wu, Yizhuo Wang, Liwen Jin, Mei Jin, Junyang Zhao, Brenda L. Gallie, Xiaoli Ma, and Qiyan Li

Subjects
Pars plana, Endoresection, medicine.medical_specialty, business.industry, medicine.medical_treatment, Treatment outcome, Follow up studies, Retrospective cohort study, Vitrectomy, Intraocular Retinoblastoma, 03 medical and health sciences, Ophthalmology, 0302 clinical medicine, medicine.anatomical_structure, Refractory, 030220 oncology & carcinogenesis, 030221 ophthalmology & optometry, medicine, business
Published
2018

34. Robustness, sensitivity and reproducibility of eDNA metabarcoding as an environmental biomonitoring tool in coastal salmon aquaculture – An inter-laboratory study

Author

Larissa Frühe, Verena Dully, Thorsten Stoeck, Iain Berrill, Martin Daumer, Alexander Thielen, Heinrich Balliet, and Sheena Gallie

Subjects
Salmon aquaculture, 0106 biological sciences, Infaunal Quality Index, Macroinvertebrates, Ecology, Beta diversity, General Decision Sciences, Replicate, 010501 environmental sciences, Biology, 010603 evolutionary biology, 01 natural sciences, Benthic bacterial communities, eDNA metabarcoding, Fishery, Taxon, Environmental compliance monitoring, Biomonitoring, Alpha diversity, Environmental impact assessment, Environmental DNA, QH540-549.5, Ecology, Evolution, Behavior and Systematics, Environmental quality, 0105 earth and related environmental sciences
Abstract

Environmental DNA metabarcoding of benthic bacterial communities emerged as a very powerful technology to assess environmental disturbance effects of coastal salmon aquaculture. A prerequisite for the implementation of this approach into compliance monitoring regulations is its robustness and reproducibility of obtained results. In the framework of regular compliance monitoring of a Scottish salmon farm, we therefore collected sediment samples along a transect from the salmon cages to reference sites in duplicates (biological replicates). Aliquots of both biological replicate samples were then processed by two different laboratories using independently the same eDNA metabarcoding protocol (technical replicates). Measures of alpha diversity and beta diversity, as well as taxonomic profiles of benthic bacterial communities were highly congruent among technical replicates, which even showed less variations then the biological replicates that were processed within each laboratory. Both technical replicate datasets identified the same bacterial indicator taxon groups and ASVs that are characteristic for the environmental quality (EQ) categories to which each of the samples was assigned based on traditional macroinvertebrate biomonitoring of the same samples. In a supervised machine learning (SML) approach, we could classify all individual samples from one technical replicate dataset into the correct EQ category using all samples of the other technical replicate dataset as a training dataset for the SML algorithm. We conclude that eDNA metabarcoding is sufficiently robust that different laboratories come to the same conclusions regarding officially regulated action criteria for environmental impact assessments in salmon aquaculture.

Published
2021

35. Eukaryotic Initiation Factor eIFiso4G1 and eIFiso4G2 Are Isoforms Exhibiting Distinct Functional Differences in Supporting Translation in Arabidopsis

Author

Daniel R. Gallie

Subjects
0301 basic medicine, Gene isoform, viruses, Molecular Sequence Data, Arabidopsis, Sigma Factor, Biology, environment and public health, Biochemistry, 03 medical and health sciences, chemistry.chemical_compound, Eukaryotic translation, Gene Expression Regulation, Plant, Genes, Reporter, Luciferases, Firefly, Eukaryotic initiation factor, Databases, Genetic, Protein Isoforms, Initiation factor, Amino Acid Sequence, Eukaryotic Initiation Factors, EIF4B, Peptide Chain Initiation, Translational, Molecular Biology, Conserved Sequence, Phylogeny, Genetics, Base Sequence, Arabidopsis Proteins, EIF4G, EIF4E, food and beverages, DNA, Cell Biology, Plants, Genetically Modified, 030104 developmental biology, chemistry, Protein Synthesis and Degradation, Protein Biosynthesis, eIF4A, Mutation, Eukaryotic Initiation Factor-4G, Sequence Alignment
Abstract

The eukaryotic translation initiation factor (eIF) 4G is required during protein synthesis to promote the assembly of several factors involved in the recruitment of a 40S ribosomal subunit to an mRNA. Although many eukaryotes express two eIF4G isoforms that are highly similar, the eIF4G isoforms in plants, referred to as eIF4G and eIFiso4G, are highly divergent in size, sequence, and domain organization but both can interact with eIF4A, eIF4B, eIF4E isoforms, and the poly(A)-binding protein. Nevertheless, eIF4G and eIFiso4G from wheat exhibit preferences in the mRNAs they translate optimally. For example, mRNA containing the 5'-leader (called Ω) of tobacco mosaic virus preferentially uses eIF4G in wheat germ lysate. In this study, the eIF4G isoform specificity of Ω was used to examine functional differences of the eIF4G isoforms in Arabidopsis. As in wheat, Ω-mediated translation was reduced in an eif4g null mutant. Loss of the eIFiso4G1 isoform, which is similar in sequence to wheat eIFiso4G, did not substantially affect Ω-mediated translation. However, loss of the eIFiso4G2 isoform substantially reduced Ω-mediated translation. eIFiso4G2 is substantially divergent from eIFiso4G1 and is present only in the Brassicaceae, suggesting a recent evolution. eIFiso4G2 isoforms exhibit sequence-specific differences in regions representing partner protein and RNA binding sites. Loss of any eIF4G isoform also resulted in a substantial reduction in reporter transcript level. These results suggest that eIFiso4G2 appeared late in plant evolution and exhibits more functional similarity with eIF4G than with eIFiso4G1 during Ω-mediated translation.

Published
2016

40. Socioeconomic and psychological impact of treatment for unilateral intraocular retinoblastoma

Author

Brenda L. Gallie, Mona Hamdy Ashry, Ahmed Souka, Helen Dimaras, and Sameh E. Soliman

Subjects
Male, Pediatrics, medicine.medical_specialty, Retinal Neoplasms, Enucleation, Intraocular Retinoblastoma, Eye Enucleation, Hospitals, University, Treatment and control groups, Cost of Illness, Adaptation, Psychological, medicine, Humans, Child, Neoplasm Staging, Retrospective Studies, Salvage Therapy, Retinoblastoma, business.industry, Infant, Organ Preservation, medicine.disease, Combined Modality Therapy, eye diseases, Surgery, Survival Rate, Ophthalmology, Socioeconomic Factors, Child, Preschool, Disease Progression, Population study, Egypt, Female, Observational study, business, Social Adjustment, Unilateral Retinoblastoma, Psychosocial
Abstract

To identify the socioeconomic and psychosocial impacts of clinical treatment decisions for advanced unilateral intraocular retinoblastoma.Retrospective observational case series.institutional study at Alexandria Main University Hospital.records of 66 unilateral retinoblastoma cases treated from May 2005 to May 2013 were retrospectively reviewed. Sixty cases were eligible (International Intraocular Retinoblastoma Classification [IIRC] group C, D or E).two treatment groups were compared: enucleation vs. salvage treatment. Salvage treatment eyes were further subdivided based on IIRC group. Six socioeconomic parameters (financial burden, financial impact, psychological, social, medical and tumor impacts) were scored. Parameter scores ranged from 0 to 3, for overall score range 0 (no adverse impact) to 18 (severe adverse impact).derived Socioeconomic scores were correlated with treatment and outcomes.The enucleation group (28 eyes) had a median overall Socioeconomic score of 4/18, significantly lower than the salvage treatment group (32 eyes), median score 11/18 (P0.01). Socioeconomic score varied with IIRC group. Attempted eye salvage failed in 25 children, due to uncontrolled tumor (44%) and socioeconomic impact of cumulative therapies (56%). Treatment duration and Socioeconomic score were higher for the 5 children in the salvage treatment group who developed metastatic disease compared to those without metastasis (P0.01).The socioeconomic and psychosocial impacts of attempted ocular salvage for unilateral intraocular retinoblastoma are severe, in comparison to primary enucleation. Primary enucleation is a good treatment for unilateral retinoblastoma.

Published
2015

41. Eukaryotic Translation Initiation Factor eIFiso4G Is Required to Regulate Violaxanthin De-epoxidase Expression in Arabidopsis

Author

Zhong Chen, Blair Jolley, Daniel R. Gallie, and Christian Caldwell

Subjects
Chlorophyll, Mutant, Arabidopsis, Xanthophylls, Biochemistry, Violaxanthin de-epoxidase, chemistry.chemical_compound, Eukaryotic translation, Gene Expression Regulation, Plant, Protein Isoforms, Initiation factor, Biomass, Photosynthesis, Molecular Biology, chemistry.chemical_classification, biology, Arabidopsis Proteins, EIF4G, food and beverages, Cell Biology, Carbon Dioxide, biology.organism_classification, chemistry, Protein Synthesis and Degradation, Xanthophyll, Eukaryotic Initiation Factor-4G, Oxidoreductases, Violaxanthin
Abstract

The eukaryotic translation initiation factor (eIF) 4G is a scaffold protein that organizes the assembly of those initiation factors needed to recruit the 40 S ribosomal subunit to an mRNA. Plants, like many eukaryotes, express two eIF4G isoforms. eIFiso4G, one of the isoforms specific to plants, is unique among eukaryotic eIF4G proteins in that it is highly divergent and unusually small in size, raising the possibility of functional specialization. In this study, the role of eIFiso4G in plant growth was investigated using null mutants for the eIF4G isoforms in Arabidopsis. eIFiso4G loss of function mutants exhibited smaller cell, leaf, plant size, and biomass accumulation that correlated with its reduced photosynthetic activity, phenotypes not observed with the eIF4G loss of function mutant. Although no change in photorespiration or dark respiration was observed in the eIFiso4G loss of function mutant, a reduction in chlorophyll levels and an increase in the level of nonphotochemical quenching were observed. An increase in xanthophyll cycle activity and the generation of reactive oxygen species contributed to the qE and qI components of nonphotochemical quenching, respectively. An increase in the transcript and protein levels of violaxanthin de-epoxidase in the eIFiso4G loss of function mutant and an increase in its xanthophyll de-epoxidation state correlated with the higher qE associated with loss of eIFiso4G expression. These observations indicate that eIFiso4G expression is required to regulate violaxanthin de-epoxidase expression and to support photosynthetic activity.

Published
2014

42. Reply

Author

Alison H. Skalet, Dan S. Gombos, Brenda L. Gallie, Jonathan W. Kim, Carol L. Shields, Brian P. Marr, Sharon E. Plon, and Patricia Chévez-Barrios

Subjects
Oncologists, Pathologists, Ophthalmology, Consensus, Retinoblastoma, Humans, Child, Eye, United States
Published
2018

44. Retinal mapping of heritable retinoblastoma

Author

Sameh E. Soliman, Brenda L. Gallie, and Stefan J. Langenegger

Subjects
Ophthalmology, medicine.medical_specialty, chemistry.chemical_compound, chemistry, business.industry, Retinoblastoma, Pediatrics, Perinatology and Child Health, Medicine, Retinal, business, medicine.disease
Published
2019

45. Reply

Author

Skalet, Alison H., primary, Gombos, Dan S., additional, Gallie, Brenda L., additional, Kim, Jonathan W., additional, Shields, Carol L., additional, Marr, Brian P., additional, Plon, Sharon E., additional, and Chévez-Barrios, Patricia, additional

Published
2018
Full Text
View/download PDF

46. Reply

Author

Zhao, Junyang, primary, Li, Qiyan, additional, Wu, Songyi, additional, Jin, Liwen, additional, Ma, Xiaolin, additional, Jin, Mei, additional, Wang, Yizhuo, additional, and Gallie, Brenda, additional

Published
2018
Full Text
View/download PDF

47. Screening Children at Risk for Retinoblastoma

Author

Skalet, Alison H., primary, Gombos, Dan S., additional, Gallie, Brenda L., additional, Kim, Jonathan W., additional, Shields, Carol L., additional, Marr, Brian P., additional, Plon, Sharon E., additional, and Chévez-Barrios, Patricia, additional

Published
2018
Full Text
View/download PDF

49. Tibiofemoral contact forces protect against articular tissue damage in the anterior cruciate ligament reconstructed knee, but not if there is concurent meniscal injury

Author

Christopher J. Vertullo, Kim L Bennell, X. Wang, Karine Fortin, Jason M. Konrath, T. Whitehead, David J. Saxby, Flavia M. Cicuttini, A. Bryant, Luca Modenese, Pauline Gerus, Price Gallie, Julian A. Feller, David Lloyd, and Tim V. Wrigley

Subjects
030203 arthritis & rheumatology, 0301 basic medicine, Orthodontics, medicine.medical_specialty, business.industry, Anterior cruciate ligament, Biomedical Engineering, Rheumatology, Contact force, 03 medical and health sciences, 030104 developmental biology, 0302 clinical medicine, Meniscal injury, medicine.anatomical_structure, Internal medicine, Tissue damage, Orthopedic surgery, Medicine, Orthopedics and Sports Medicine, business
Published
2016
Full Text
View/download PDF

50. Violaxanthin de-epoxidase is rate-limiting for non-photochemical quenching under subsaturating light or during chilling in Arabidopsis

Author

Zhong Chen and Daniel R. Gallie

Subjects
Photoinhibition, Light, Photosystem II, Physiology, Arabidopsis, Plant Science, Xanthophylls, Biology, Violaxanthin de-epoxidase, chemistry.chemical_compound, Stress, Physiological, Genetics, chemistry.chemical_classification, Arabidopsis Proteins, Antheraxanthin, Non-photochemical quenching, Photosystem II Protein Complex, Pigments, Biological, Adaptation, Physiological, Enzymes, Cold Temperature, Zeaxanthin, chemistry, Biochemistry, Xanthophyll, Biophysics, Reactive Oxygen Species, Violaxanthin
Abstract

In response to conditions of excess light energy, plants induce non-photochemical quenching (NPQ) as a protective mechanism to prevent over reduction of photosystem II and the generation of reactive oxygen species (ROS). The xanthophyll cycle, which contributes significantly to reversible NPQ to thermally dissipate excess absorbed light energy, involves de-epoxidation of violaxanthin and antheraxanthin to zeaxanthin in response to excess light energy. The activation of violaxanthin de-epoxidase (VDE), which catalyzes the de-epoxidation reaction, requires the generation of a light-induced, transthylakoid pH gradient. In this work, we overexpressed or repressed the expression of VDE in Arabidopsis (Arabidopsis thaliana) to examine whether VDE is rate-limiting for the induction of NPQ. Increasing VDE expression increased the de-epoxidation state of xanthophyll pigments, the rate of NPQ induction, and the level of NPQ achieved under subsaturating light. In saturating light, however, overexpression of VDE did not increase the xanthophyll pigment de-epoxidation state, the level of NPQ achieved following its initial induction, or substantially improve tolerance to high light. Only under chilling, which reduces VDE activity, did an increase in VDE expression provide slightly greater phototolerance. Repression of VDE expression impaired violaxanthin de-epoxidation, reduced the generation of NPQ, and lowered the level of NPQ achieved while increasing photosensitivity. These results demonstrate that the endogenous level of VDE is rate-limiting for NPQ in Arabidopsis under subsaturating but not saturating light and can become rate-limiting under chilling conditions. These results also show that increasing VDE expression confers greater phototolerance mainly under conditions which limit endogenous VDE activity.

Published
2012

Catalog

Books, media, physical & digital resources
See catalog results